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Awareness of genetic counselling and risk assessment is imperative for women to seek 
out genetic services. The purpose of this study is to determine the level of genetic 
counselling and acceptability of genetic counselling by breast cancer survivors, at the time 
of diagnosis, and the female members of their families, after the diagnosis of the patient 
within their family, with a view to developing recommendations based on the findings of 
the study. Two questionnaires were administered to a conveniently selected sample of 48 
women; 28 were breast cancer survivors from the Cancer Association of South Africa’s 
breast cancer support group and 20 women from the general public. Interviews were then 
conducted with four randomly selected patients and their family members. A total of 12 
participants were interviewed: four breast cancer survivors and eight family members, 
including two spouses and six children. During the interviews one breast cancer patient 
who was counselled by a psychologist indicated that she was not satisfied with the 
information she had been given and that further information on the genetics, recurrence, 
prognosis and family risk should have been provided as she considered this to be 
essential. The three patients who were not counselled were of the opinion that counselling 
on the genetics and risks of breast cancer would have been very useful. Four (50%) of the 
eight family members interviewed, indicated that they were not offered genetic counselling 
and would not be interested in knowing about the risks associated with breast cancer. Of 
the remaining four, two (25%) indicated that although they were not offered genetic 
counselling they would be interested in genetic counselling and learning about the risks 
associated with breast cancer as such information would be of great value. In terms of a 
breast cancer risk assessment, four of the eight family members (50%) indicated they 
were not interested with one further explaining that she might be interested at a later 
stage. The remaining four family members (50%) indicated their interest in attending a 
breast cancer risk assessment. In conclusion, educational interventions are required to 
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CHAPTER I: INTRODUCTION 
 
1.1 Introduction 
Cancer refers to any one of a large number of diseases characterized by the development 
of abnormal cells that divide uncontrollably and have the ability to infiltrate and destroy 
normal body tissue. Cancer also has the ability to spread throughout the body (Mayoclinic, 
2014). The development of any form of cancer is a multi-step process characterized by 
genetic alterations that influence key cellular pathways involved in growth and 
development (Osborne et al., 2004).  
 
Cancer cells have five basic properties, namely their ability to 
• grow uncontrollably, 
• invade surrounding tissues, 
• enter the bloodstream or other channels, such as lymph vessels, and travel to different 
locations in the body, 
• establish secondary tumours in other organs, and 
• produce substances that interfere with the control of various body functions, such as 
affecting nerves, muscles, and salt regulation (Buckman, 1997). 
 
1.2 Epidemiology of cancer  
According to the 2004 Global Burden of Disease, cancers ranked as the third-highest 
cause of mortality in men and women globally, accounting for 13.4% in men and 11.8% in 
women (WHO, 2008). Worldwide, there were 14.1 million new cancer cases, 8.2 million 
cancer deaths and 32.6 million people living with cancer (within a 5-year period of 
diagnosis) in 2012 (International Association for Research on Cancer [IARC], 2013). An 
estimated 57% (8 million) of the new cancer cases, 65% (5.3 million) of the cancer deaths 
and 48% (15.6 million) of the 5-year prevalent cancer cases occurred in the developing 
regions, which include south-eastern Asia, south-central Asia, eastern, western, northern 
and middle Africa, and central America (IARC, 2013).  
 
Carcinoma of the lung (1.8 million, 13.0% of the total), breast (1.7 million, 11.9%), and 
colorectal cancer (1.4 million, 9.7%) were the most commonly diagnosed cancers 
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worldwide whilst cancers of the lung (1.6 million, 19.4% of the total), liver (0.8 million, 
9.1%), and stomach (0.7 million, 8.8%) were the most common cause of mortality globally 
in 2011 (IARC, 2013). 
 
Breast, colon or rectum, and lung cancer are most common in women whilst prostate, 
lung, and colon or rectum cancer are the most common cancers amongst men (Shibuya et 
al., 2002). 
 
In 2012, 1.7 million women were diagnosed with breast cancer, and 6.3 million women 
who had been diagnosed with breast cancer in the previous five years were still alive 
(IARC 2013). The incidence of breast cancer has increased by more than 20%, while 
mortality has increased by 14% since 2008 (IARC, 2013). Not only is breast cancer the 
most common cause of cancer death among women (522 000 deaths in 2012), it is also 
the most frequently diagnosed cancer among women in 140 of 184 countries worldwide, 
representing one in four of all cancers in women (IARC, 2013).  
 
It is estimated that one in nine females will develop cancer of the breast in their lifetime; 
80% will be post-menopausal, mostly aged between 60 and 64 (Ogden, 2004). In the 
United Kingdom (UK), breast cancer is the most common cancer, with approximately 
49,560 women and 400 men being diagnosed with the disease annually (Cancer Research 
UK, 2012). Women in the UK have a one in 8 lifetime risk of developing breast cancer, 
with most women who develop breast cancer having been through menopause, and about 
20% being under 50 years of age (Cancer Research UK, 2012).   
 
Although prevalence of breast cancer is lower in South Africa than Europe (41 per 100 000 
in South Africa versus 89.1 per 100 000 in the UK), the overall African mortality rates are 
among the highest in the world – a direct result of a lack of services, transport difficulties 
and the resultant late presentation. More people succumb to all cancers daily worldwide 
than the sum of HIV & AIDS, TB and malaria (Bateman, 2012). 
 
The National Cancer Registry (2004) reported that breast cancer is the most common 
cancer within the South African female population. However, there are significant 
population differences, with cancer of the breast being the commonest cancer in Asian 
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(33.99%) and Coloured women (25.01%), but ranking second to cervical and basal cell 
carcinomas (BCC) in black (17.31%) and white women (19.56%), respectively (Mqoqi et 
al., 2004).   
 
By 2050, the incidence rates of breast cancer worldwide are conditionally predicted to 
reach six times the current levels (Bateman, 2012).  
 
Although the incidence rates of breast cancer has increased, the improved screening and 
treatment, has provided women with a better chance of survival. In the United Kingdom, 
more than 90% of women with stage 1 breast cancer survived 5 years or more, and more 
than 85% survived over 10 years. More than 70% of women with stage 2 breast cancer 
survived more than 5 years, whilst more than 60% survived more than 10 years. There 
was a 50% 5-year survival rate and a 40% 10-year survival rate in women with stage 3 
tumours (Cancer Research UK, 2012).  
 
According to the American Cancer Society’s 2011 report, the five-year relative survival rate 
for women with breast cancer is approximately 90%. Regarding breast cancer survival in 
Africa, the Zimbabwe Cancer registry indicated that survival of black (African) women 
diagnosed with breast cancer was 32,6% after five years, compared with 58,2% among 
white women in the same city (Harare) (Williams et al., 2006). Similarly, Ghafoor et al. 
(2002) and Jemal et al. (2003) have shown that five-year survival rates amongst African-
American females with breast cancer is lower (73 percent), as compared with white 
women (88 percent), at all stages of diagnosis. 
 
In South Africa, delayed screening of women by overloaded and often understaffed public 
sector public health clinics does not increase the cancer detection rate of 1 in 26 women 
daily, nor improve on the current ratio of 1 in 7 dying of the disease (Bateman, 2012). 
 
1.3 Statement of the problem  
Genetic counselling is the process by which patients or relatives at risk of an inherited 
disorder are advised of the consequences and nature of the disorder, the probability of 
developing or transmitting it, and the options open to them in management and planning of 
families (Wikipedia, 2014). Genetic counselling will therefore provide both the patient and 
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the family with the necessary information and advice about their breast cancer. Genetic 
counselling will be suited to the individual needs of the patient and her family, thereby 
providing them with relevant information to make informed choices. 
 
Considerable research exists on the steps in diagnosing breast cancer; that is, from the 
point of screening through to treatment of breast cancer. However, not much literature is 
available on genetic counselling and risk assessments for female family members of 
breast cancer patients. 
 
1.4 Motivation for the study  
Canadian, UK and USA-based research is available on genetic counselling and risk 
assessments for female family members of breast cancer patients but there is little 
reference to South African-based studies. It was therefore important to conduct a study on 
the need for genetic counselling and risk assessments for high risk women in South Africa, 
including women with a family history of the disease. 
 
1.5 Purpose of the study  
The purpose of the study was to determine the level of genetic counselling and 
acceptability of genetic counselling by breast cancer survivors, at the time of diagnosis, 
and the female members of their families, after the diagnosis of the patient in their family, 
with a view to making recommendations based on the findings.  
 
1.6 Research objectives 
In order to achieve the purpose, the objectives of the study were to: 
 
• Determine the participants’ socio-demographic profile.  
• Ascertain the awareness and factors that affected the uptake of genetic counselling 
by breast cancer patients, their female family members and women in the general 
public in the Msunduzi Municipality in 2003. 
• Assess the willingness of female children of a breast cancer patient to undergo 




1.7 Significance of the study  
The findings of this study should provide an analysis of acceptability and uptake of genetic 
counselling and stimulate further research in this field. 
 
1.8 Assumptions underlying the study  
Assumptions are basic principles that are assumed to be true based on logic and reason, 
without proof or verification (Brink et al., 2006). Assumptions influence the logic of the 
study which leads to more rigorous study development. The assumptions underlying the 
study were as follows:  
 
• Genetic counselling and risk assessments are offered for female offspring of breast 
cancer patients. 
• If not, female offspring would be interested in consulting with a genetic counsellor 
and having a risk assessment conducted, to determine their risk of developing the 
disease. 
 
1.9 Structure of the dissertation  
The dissertation consists of six chapters. Chapter 1 introduces the study, including the 
epidemiology of cancer; statement of the problem; motivation for the study; purpose, 
objectives and significance of the study, and assumptions underlying the study. 
 
Chapter 2 covers the literature review on gene mutations, genes that contribute to the 
development of breast cancer, biomarkers for breast cancer, risk factors associated with 
breast cancer, genetic counselling and testing, knowledge of and attitudes towards breast 
cancer screening and genetic testing, and the Health Belief Model of Health Promotion as 
a conceptual framework. 
 
Chapter 3 describes the research design and methodology. 
 





Chapter 5 discusses the results of the study. 
 
Chapter 6 provides a summary of the study and makes recommendations. 
 
1.10 Summary 
This chapter discussed the research problem, purpose, objectives and significance of the 



















CHAPTER II: LITERATURE REVIEW 
 
2.1 Introduction  
This chapter covers the literature review conducted for the study. The literature review 
focused on breast cancer, awareness and factors that affect the uptake of genetic 
counselling and genetic counselling for family members of breast cancer patients. This 
included the risk factors associated with breast cancer; gene mutations; genes that 
contribute to the development of breast cancer; biomarkers for breast cancer; genetic 
counselling and testing; knowledge of and attitudes towards breast cancer screening and 
genetic testing; and the Health Belief Model of Health Promotion as a conceptual 
framework. 
 
2.2 Purpose of the literature review  
Significant progress has been made in diagnosing and treating breast cancer patients. 
Genetic counselling and risk assessments for female family members of breast cancer 
patients, as well as raising awareness and educating them on risk factors and primary 
prevention, do not play a prominent role in the South African health care system. The 
focus is only on the patient without consideration being given to women in her family who 
may be at risk of developing the disease. Accordingly, the researcher attempted to present 
the importance of genetic counselling and risk assessment as a primary means of 
prevention to females with a higher risk of developing cancer of the breast. 
 
2.3 Scope of the literature review 
The literature review focused on studies that examined the risk factors for breast cancer 
and the link to genetic markers; genes involved in breast cancer; diagnosis of breast 
cancer; treatment; uptake of genetic counselling and risk assessment, and patient 
knowledge. This included genes mutation; genes that contribute to the development of 
breast cancer; biomarkers for breast cancer; risk factors associated with breast cancer; 
genetic counselling and testing; knowledge of and attitudes towards breast cancer 





The review excluded studies on co-morbidity with breast cancer, such as HIV and AIDS 
and non-communicable diseases. 
  
2.4 Sources of literature reviewed  
The electronic databases PubMed; Google Scholar; Google; Susan G. Komen; American 
Cancer Society and the National Health Laboratory Services were used to search for 
information and studies on breast cancer. The researcher used the keywords and phrases: 
breast cancer; breast cancer risk factors; Breast Cancer gene 1(BRCA1); Breast Cancer 
gene 2 (BRCA2); P53 tumour suppressor gene; Bak and Bax gene mutations; Human 
Epidermal growth factor receptor 1 (HER 1) and receptor 2 (HER 2) gene polymorphisms;  
biomarkers for breast cancer; knowledge of and attitudes toward breast cancer screening; 
genetic counselling in breast cancer; uptake of genetic counselling; barriers to genetic 
counselling, and breast cancer risk assessment. 
 
2.5 Risk factors linked to breast cancer development  
Cancer risk is inherited in a quantitative manner; consequently, numerous genetic and 
environmental factors selectively lead to the expression of the disease (Alberg & 
Helzlsouer, 1997; Smith et al., 2001; Byers et al., 2002). Established breast cancer risk 
factors include not only inherited susceptibility but also endogenous hormone levels, early 
age at first menstruation, menopause at a late age, giving birth to a first child at an older 
age, hormone replacement therapy, a high fat diet, alcohol consumption, smoking, stress 
and physical activity (Allan et al., 1992, Alberg & Helzlsouer, 1997; Feigelson & 
Henderson, 2000; Sampson & Fenlon, 2002; Ogden, 2004).  
 
The incidence of breast cancer in Brazil and trends amongst younger women has 
increased since 1980 (Carraro et al., 2013). In the 25 to 29 year age range, there was an 
increase from 6.4 to 7.8 per 100,000 females; in the 30 to 34 year age range, incidence 
increased from 19 to 27.6 per 100,000 women (Ortega et al., 2010). Risk factors for early 
development of breast cancer are still not well understood; however, a family history of 





Age continues to be the most significant risk factor in developing breast cancer (Wang et 
al., 2011). Estimates show that 20% of Americans will be older than the age of 65 by 2030. 
Approximately 50% of breast cancer patients are older than 65 years and approximately 
35% are older than 70 years (Holmes & Muss, 2003; Society, 2003). However, most of the 
variation in breast cancer risk across populations and among individuals is due to 
environmental factors that are not inherited (Byers et al., 2002).   
 
a. Breast density 
Mammographic breast density is probably the least valued and used risk factor when 
investigating cancer of the breast (Liotta et al., 2001; Chung et al., 2002; van de Vijver et 
al., 2002). Breast density is inheritable, although the role of breast density to a greater risk 
is not dependent on the risk associated with BRCA1 and BRCA2 mutations (Bremer et al., 
2002). Bremer et al. (2002) reported that the average relative risk of breast cancer in 
women with greater breast density as compared with women with a lower breast density is 
4. Genetic factors that determine breast cancer probably also play a role in breast cancer 
(van de Vijver et al., 2002). 
 
b. Genetic risk factors 
Breast cancer can be inherited when there are cellular changes which make a female 
susceptible to developing the disease and these germ-line mutations account for the vast 
incidence of breast cancer, especially those women who develop the disease in both 
breasts at a young age (Joy et al., 2005). Genetic inheritance and mutations within the 
BRCA1 and BRCA2 genes influences the risk of women contracting breast cancer (Smith 
et al., 2001; Byers et al., 2002). However, less than 10% of all breast cancer cases are 
considered to be a result of inherited mutations, BRCA1 and BRCA2, which individually 
increase risk by a significant amount (Massoud & Gambhir, 2003).  
 
Within the South African context approximately 5 – 10% of breast cancer cases are 
directly due to an inherited susceptibility (Schlebusch et al., 2010). In South Africa, BRCA1 
and BRCA2 disease-causing mutations are responsible for 19 and 47% of familial breast 




Mutations that are common in the South African population are, the 3 mutations which 
make up >90% of BRCA mutations in Afrikaners – BRCA1 1493delC, BRCA1 2760G>T 
(p.Glu881X) and BRCA2 8162delG; the 3 mutations known to be common in those of 
Ashkenazi Jewish ancestry – BRCA1 185delAG, BRCA1 1493insC and BRCA2 
6174delT; and a recently described mutation that has been found to be more common in 
people of Xhosa and mixed ancestry in the Western Cape (BRCA2 5999del4) was added 
to the panel of ‘common mutations’ in 2009 (Schoeman et al., 2013). 
 
c. Environmental risk factors 
The majority of breast cancers result from an increase of cellular changes which take 
place over time; hence age is a significant factor because the longer a person lives, the 
more time there is for mutations to accumulate (Joy et al., 2005). These types of changes 
are due to exposure to carcinogens from the external environment, or from extreme 
exposure to substances which promote breast cancer within the body, such as circulating 
hormones, or may even be due to random mutations that occur during cell division (Joy et 
al., 2005). 
 
d. Early onset of menstruation 
Oestrogen is known to accelerate the development of half of all breast cancers, and the 
longer breast tissue is exposed to the natural oestrogens circulating in a woman’s body, 
the greater her risk of breast cancer will be as she ages (Baron-Faust, 1995; Khan et al., 
1998; Haiman et al., 2002; Ogden, 2004).  Therefore, beginning menstruation before the 
age of twelve, increases a woman’s risk by approximately one and a half times that of 
women who  begin menstruating after the age of fifteen (Baron-Faust, 1995; Ogden, 
2004). 
 
e. Age at first pregnancy 
Delaying childbirth until the late thirties or early forties may double or treble some women’s 
risk for the development of breast cancer (Baron-Faust, 1995; Sampson & Fenlon, 2002) 
compared to women who give birth to their first child before the age of twenty (Baron-
Faust, 1995; Buckman, 1997; Ebrahimi et al., 2002).  Scientists believe that the protective 
effect gained from early pregnancy may be due to the changes in breast cells during 
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pregnancy and lactation, where the lobules produce milk that is transported from the ducts 
to the nipple openings during breastfeeding (Ogden, 2004). Cells that produce milk are 
fully matured and are not as sensitive to DNA damage, resulting in a declined susceptibility 
to mutations in breast cells of females who gave birth at an early age (Clark et al., 2005). 
 
f. Late onset of menopause 
The amount of exposure to natural oestrogen also affects women who are at the end of 
their reproductive cycle (Baron-Faust, 1995).  Women who enter menopause after fifty-five 
years of age (Sampson & Fenlon, 2002) are at twice the risk of developing breast cancer 
compared with women whose menopause occurs before age forty-five (Baron-Faust, 
1995).  Furthermore, women with surgically removed ovaries prior to the natural age of 
menopause are at an even lower risk than women who enter an early natural menopause 
(Baron-Faust, 1995). 
 
g. Use of hormone replacement therapy (HRT) 
The use of hormone replacement therapy (HRT) by postmenopausal women is linked to a 
higher risk of developing breast cancer (Lawson et al., 2001). HRT is usually given to older 
women when the breasts are less vulnerable to risk factors due to the slower rate of cell 
growth (Sampson & Fenlon, 2002). According to Sampson and Fenlon (2002), a woman’s 
chances of developing breast cancer after five years of HRT is between 45 and 47 per 
1000, and further rises to 51 per 1000 after ten years of using HRT.   
 
h. Body mass index 
In addition to the above risk factors, one that has received much attention is the 
relationship between body size (weight and height) and the risk of developing breast 
cancer (van den Brandt et al., 2000). Body mass index, which is calculated as weight 
(kg)/height2 (m2), shows a positive link with postmenopausal breast cancer risk and an 
inverse association with developing premenopausal breast cancer (Hunter & Willett, 1993, 
Swanson et al., 1996, Trentham-Dietz et al., 1997).  A positive link between breast cancer 
risk and adult height was seen mostly for postmenopausal women (Hunter & Willett, 1993; 




Obesity in premenopausal women is thought to protect women from developing breast 
cancer due to frequent anovulatory menstrual cycles, resulting in lower levels of estradiol 
and progesterone and decreased luteal phase progesterone levels in ovulatory cycles 
(Stoll, 1994).  However, it is not clear as to the level of obesity that is needed to produce 
adequate anovulatory cycles to decrease the risk of developing breast cancer (Ursin et al., 
1994).   
 
In postmenopausal women, it has been proposed that the distribution of fat is more 
predictive of breast cancer risk than body mass (Stoll, 1994).  Considerable data indicates 
that obesity is linked to a higher risk of breast cancer in postmenopausal women who have 
not used HRT (National Cancer Institute, 2014).This may be because in postmenopausal 
women, the production of ovarian oestrogen is lessened, and oestrogen, which may assist 
the growth of tumours, comes about largely from the aromatization of androstenedione 
that occurs primarily in adipose tissue (van den Brandt et al., 2000).   
 
Obesity is constantly recognized as linked to cancer, where obesity contributes to a higher 
risk of cancer incidence and increases mortality as shown in three large population-based 
cohort studies (Calle et al., 2003; Reeves et al., 2007; Song et al., 2008). 
 
2.6 Gene mutation  
Germline mutations are considered important contributors to disease-causing issues in the 
younger breast cancer patients globally (Carraro et al., 2013).When cancer develops it is 
due to mutations in the body’s cells. Young females have breast tissue that is sensitive to 
DNA damage due to cancer-related causes (Clark et al., 2005). According to the National 
Cancer Institute (NCI), inheriting a mutation in either BRCA1 or 2 not only increases a 
woman’s chance of developing breast cancer, but these women also have an increased 
risk for the development of ovarian and other cancers (Zielinski, 2008).   
 
2.7 Genes that contribute to the development of breast cancer  
Genes that control normal cell division are called proto-oncogenes and are active where 
and when high rates of cell division are required (Lewis, 1994). Proto-oncogenes may be 
activated into oncogenes, cancer-causing genes, by point mutations, gene amplification or 
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gene translocation (Lewis, 1994) so that far more protein encoded by that gene is present, 
therefore enhancing its role (Osborne et al., 2004).  
 
Oncogene refers to those genes in which alterations or mutations cause a gain-of-function 
effect that contributes to the development of a malignant phenotype (Osborne et al., 2004). 
However, full development of a cancerous state usually requires additional mutations, 
typically deletions or point mutations (Lewis, 1994), which affect genes normally involved 
in the restraint of cell growth (Snustad & Simmons, 2003). These mutations define a 
second class of cancer-related genes, the anti-oncogenes or recessive oncogenes (Lewis, 
1994), better known as tumour suppressor genes (Snustad & Simmons, 2003). These 
genes lead to an inability to function which contributes to malignant phenotypes (Osborne 
et al., 2004).  
 
The tendency to develop certain types of cancer is known to run in families and to develop 
due to a combination of mutational events (Weaver, 1992). Abnormal genes are believed 
to account for 5 to 10% of all cancers of the breast (Ogden, 2004). There has been 
considerable progress in identifying these genes responsible for breast cancer (Cornelisse 
et al., 1996). Two genes, BRCA1 and BRCA2, are the most important tumour suppressor 
genes related to a higher risk of breast and ovarian cancers in families (Ogden, 2004). 
 
BRCA1 and BRCA2 are usually involved in regulating cell growth, but in some families the 
gene has been altered so that it no longer functions correctly (Sampson & Fenlon, 2002). 
Carraro et al. (2013) found that in 10 to 40% of cases an early onset of familial breast 
cancer was associated with mutations in BRCA1 and BRCA2. 
 
BRCA1 and BRCA2 are the two most common genes associated with breast cancer and 
should women inherit a mutation in one of these genes their chances of developing cancer 
of the breast in their lifetime would be 36 to 85% (Zielinski, 2008). BRCA1 and BRCA2 are 
part of a group of genes known as tumour suppressor genes which assist in controlling cell 
division; BRCA1 and BRCA2 repair damaged DNA (Zielinski, 2008). 
 
Regarding non-familial breast cancer, Akbari et al., (2013) found that approximately 27% 
of unselected breast cancer cases in the Bahamian population can be attributed to a 
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BRCA1 or BRCA2 mutation, a prevalence which far exceeds that of any other country. 
Other studies reported the frequency of BRCA1 or BRCA2 mutation among patients with 
an early onset of breast cancer, as ranging from 1 to 10% (Lallo et al., 2006; Fackenthal & 
Olopade, 2007; Haffty et al., 2009).  
 
Only approximately 5% of breast cancers, and particularly those diagnosed in young 
women, are as a result of mutations in the BRCA1 and BRCA2 genes (Baron-Faust, 1995; 
Lakhani, 1999; Di Prospero et al., 2001).  Patients with mutations in the BRCA1 and 
BRCA2 genes have a 10 to 25% greater risk of developing breast cancer during their 
lifetime (Snustad & Simmons, 2003). However, it is not certain that a carrier of these 
mutations will develop the disease (Sampson & Fenlon, 2002; Ogden, 2004).  
 
Human cancer cells with mutations in the BRCA1 or BRCA2 genes are hypersensitive to 
radiation and show chromosomal abnormalities (Zheng et al., 2000).  This reveals a 
potential role for both the BRCA1 and BRCA2 gene, in maintaining genetic stability by 
responding to DNA damage (Zheng et al., 2000).  Aneuploidy, chromosomal breaks and 
aberrant mitotic exchanges are all observed chromosomal abnormalities (Lee et al., 1999). 
 
a. BRCA1 gene 
Mutations in the BRCA1 gene are associated with a large percentage of hereditary cases 
of breast cancer and are found in up to 40 to 50% of families with hereditary breast cancer 
(Zheng et al., 2000). BRCA1 is inherited as an autosomal dominant gene, meaning that a 
woman has a fifty-fifty chance of inheriting a flawed copy of the gene from a heterozygous 
parent and of developing breast cancer before age fifty (Baron-Faust, 1995). These 
women also have an 85% lifetime risk of developing the disease (Di Prospero et al., 2001). 
 
Tumours of breast cancer sufferers who carry the BRCA1 mutant allele typically show 
continuous pushing margins of the tumour and lymphocytic infiltrate (Lakhani, 1999; 
Williams et al., 2006).  These features are part of the subset of characteristics that define 
medullary carcinoma (Lakhani, 1999).   It is noteworthy that carriers of a mutated gene in 
familial breast cancer families cannot be phenotypically distinguished from non-carriers, as 
two mutational events are required to eliminate both functional copies of the gene within 
the cell (Yawitch, 2001). Due to this, as well as a high occurrence of sporadic breast 
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cancer in the general population, it has been difficult to conduct linkage studies to identify 
the gene responsible for the development of breast cancer in different families. A study of 
23 extended families, including 146 cases of breast cancer, to map BRCA1 by genetic 
linkage to the interval designated 17q 12-21 on the short arm of chromosome 17 (Hall et 
al., 1990). However, there seems to be substantial variability in the ages at which breast 
cancer has been diagnosed in BRCA1 mutation carriers (Rebbeck et al., 1999).  This 
could imply that germline mutations in BRCA1 could also be a cause of the Mendelian 
pattern of breast cancer inheritance in certain families (Rebbeck et al., 1999).   
  
Steroid hormone pathways regulate BRCA1 expression (Marks et al., 1997).  Rebbeck et 
al. (1999) therefore hypothesized that allelic variation in genes controlling hormonal 
signalling known to be involved in normal breast tissue development may be involved in 
modification of BRCA1-associated cancer risk. Such is AR, the androgen-receptor gene, 
which works as a ligand-dependent transcriptional activator in response to androgens 
(Rebbeck et al., 1999). AR contains a highly polymorphic CAG trinucleotide repeat – AR-
CAG, whose length is conversely linked with the amount of transcriptional activation 
exhibited by the AR (Chamberlain et al., 1994). In order to effectively use strategies 
related to the prediction of risk or the prevention of cancer in BRCA1 carriers, detailed 
knowledge of risk-modifying factors, as well as BRCA1 mutation status, is required 
(Rebbeck et al., 1999).  
 
b. BRCA2 gene 
Tumours associated with mutations in the BRCA2 gene are phenotypically similar to 
sporadic breast tumours, as they are usually of an intermediate grade, are frequently 
hormone receptor positive and the onset of breast cancer occurs at a later age than with 
females with a mutated BRCA1 gene (Williams et al, 2006).   
 
The BRCA2 gene has been shown to be located on the short (q) arm of chromosome 13 
(Baron-Faust, 1995; Osborne et al., 2004).  Although BRCA1 and BRCA2 are similar in 
respect of features, they have different structure (Osborne et al., 2004). Over one hundred 
distinctive mutations of BRCA2 have been depicted, with the majority causing premature 
truncation of the protein, as in the case of BRCA1 (Osborne et al., 2004). BRCA1 encodes 
a phosphoprotein of 1863 amino acids (Miki et al., 1994) characterised by two structural 
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motifs at each of its flanking termini (Zheng et al., 2000). BRCA-associated ring domain or 
BARD1 is a protein which interacts with BRCA1, and following a genotoxic insult, it has 
been shown that BARD1, together with BRCA1 protein and Rad51, localise to areas of 
damaged DNA, and contributes to regulating transcription and repairing double-stranded 
DNA (Scully, 1997).  
 
It is thought that the incidence of BRCA1 and BRCA2 heterozygotes is similar within the 
general population (Osborne et al., 2004). In the Ashkenazi Jewish population, the 
mutation 6174delT takes place at a rate of 1.5%; whilst the Icelandic population has the 
mutation 999del5, which occurs at a rate of 0.5% (Osborne et al., 2004). Mutations in the 
BRCA2 gene are thought to account for about 35 percent of reported breast cancer cases 
in families (Wooster et al., 1994). 
 
c. P53 Tumour suppressor gene 
Germline mutations in approximately 10 genes that are linked to the repair of DNA have 
been shown to be linked with an inherited risk for cancer of the breast (Walsh et al., 2006). 
The tumour suppressor gene, TP53 plays an important part in the way cells respond to 
damaged DNA generating pathways involved in cell death, cell cycle arrest and the DNA 
repair mechanism to continue the cell’s genomic integrity (Brosh & Rotter, 2009).  
 
Germline mutations in TP53 are rare and are linked to a higher risk of breast cancer in 
females (Lee et al., 2012). p53 tumour suppressor gene mutations are found on the long 
(p) arm of chromosome 17 (Osborne et al., 2004), and are estimated to occur in 
approximately 20 to 30% of breast cancers (Hollstein et al., 1991). Research on the 
prevalence of TP53 germline mutations in families chosen by genetics clinics shows that 
many families with TP53 mutations fulfil the criteria for either Li-Fraumeni syndrome (LFS), 
inherited in a dominant fashion (Shannon & Smith, 2003; Goldhirsch & Gelber, 2004). Li-
Fraumeni-like or Chompret criteria are present when there is a family history of  breast, 
bone or soft tissue sarcoma, brain tumours and adrenocortical carcinomas, which are LFS-
linked cancers (Birch et al., 2001; Walsh et al., 2006; Gonzalez et al., 2009; Ruijs et al., 
2010; Osborne et al., 2004; Kruger & Apffelstaedt, 2007). Recent population-based studies 
discovered that women who had early-onset breast cancer before the age of 40, had TP53 
germline mutations (Mouchawar et al., 2010; Lalloo et al., 2006). 
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Carraro et al. (2013) found that the occurrence of germline TP53 mutations, related to the 
early development of breast cancer, is linked to Li-Fraumeni Syndrome or Li-Fraumeni-like 
syndromes. These patients have an approximately 50% chance of developing cancer by 
the time they reach their forties and a 90% chance by their eightieth year (Malkin et al., 
1990; Li, 1990). A study conducted by Lee et al.  (2012), found that in Asian areas, which 
are low-resourced and poor family history is reported, germline TP53 mutations have 
mostly been found in women with breast cancer who have a family history of LFS-linked 
cancers. 
 
Mutational inactivation of the p53 gene that controls the G1/S cell cycle checkpoint may 
avoid ceasing growth, which is what normally happens to damaged DNA, as well as 
prevent p53-mediated cell death (Zheng et al., 2000).  This enables these cells to survive 
but with serious chromosomal damage (Zheng et al., 2000) and may be the reason for the 
development of cancer in the breast in females with mutations in the p53 gene. 
 
2.8 Biomarkers for breast cancer 
Biomarkers are being sought across a broad range of events in the development of cancer 
of the breast (table 2.1) with the clinical use of biomarkers of breast cancer being limited to 














Table 2-1: Biomarkers of events in the development of breast cancer: their potential uses 
and limitations (adapted from Joy et al., 2005) 
Event Potential use for 
biomarkers 
Progress to date Key limitations 
Germ-line 
mutations 
Risk indicator Numerous mutations 
identified; genetic 
testing available for 
BRCA1 and BRCA2 
Account for only 10 
% of breast cancers 
Genetic 
polymorphisms 
Risk indicator Some candidate 
polymorphisms 
identified; thousands 
of SNPs have been 
mapped 
Validation difficult 
due to genetic 
diversity among 
different ethnic 
populations and the 
need to measure 








Loss of heterozygosity 
at several loci 
associated with 
premalignant disease, 
as well as early and 
late-stage breast 
cancer 
Unknown which, if 
any, loss of 
heterozygosity 
events are specific 
to invasive or 
metastatic cancer 
Epigenetic 









at key loci with breast 
















Studies under way on 
several over-
expressed and under-
expressed genes in 









cancer registry data 
Changes in protein 
signalling 









underway in breast 
cancer patients 





















benefits of monitoring 
a mucin, CA 15-3, 
which has received 
FDA approval for the 
detection of recurrent 
breast cancer 
Typically lack 
sensitivity for early 
malignancy and 
organ specificity; not 
elevated in all 
patients 
Angiogenesis  Risk indicator; 
prognosis; 
choosing therapy 
Research on several 
angiogenesis-related 
receptors being 
conducted to develop 










Prognosis Candidate proteases 
and inhibitors have 
been identified; 





confirmed in large 
prospective 
randomized trial 





Most biomarkers are synthesized by normal as well as malignant tissues and are only 
rarely increased in premalignant or early stage disease (Joy et al., 2005). Biomarker-
based screening may prove to be a practical means for screening women who have a 
higher risk of developing breast cancer as such biomarker-based assays could detect 
groups of proliferating cells at a preclinical stage, as well as groups of cells that may never 








2.9 Gene mutations in breast cancer  
2.9.1 Bak and Bax gene mutations 
Bak and Bak genes are the entry point to the mitochondrial passage of cell death or 
apoptosis (Kholoussi et al., 2014). Cells twice as deficient in the two multi-domain 
proapoptotic Bax and Bak do not give off cytochrome c, thereby being resistant to all 
apoptotic stimuli that initiate the inherent pathway (Lindsten et al., 2000; Wei et al., 2001). 
 
Gene transfer mediated increases in Bak protein levels boosts apoptosis induced by 
growth factor deprivation in breast cancer cells (Kholoussi et al., 2014). Bak’s primary 
function is that of a promoter of apoptosis (Pataer et al., 2000). Mutations occurring in the 
coding and promoter area of the Bax gene have been found to affect protein expression 
and the function of many cancers (Moshynska et al., 2003). Koda et al. (2004) showed that 
changes in the expression of Bak coincide with the development and progression of breast 
cancer. Eguchi et al. (2000) found that Bak expression indicated a considerable increase 
at tumour stages T3 and T4. Kholoussi et al. (2014) achieved the same outcome where 
Bak mRNA levels showed considerable increases in the T3 and T4 tumour stages.  
 
Kholoussi et al. (2014) also found that Bak expression does seem to lead to developing 
breast cancer and affects the progression of the disease. Furthermore, Kholoussi et al. 
(2014), Bax d and Bax δ could be used as a biomarker and risk factor for breast cancer. In 
addition, the G284A single nucleotide polymorphism (SNP) of Bax promoter has a 
considerable association in the breast cancer subject, which could suggest this SNP acts 
as a risk factor (Kholoussi et al., 2014). 
 
 
2.9.2 HER1 and HER2 polymorphisms 
Mutation of genes and anomalies of signalling pathway of HER1 and HER2 have often 
been associated in carcinogenesis of many solid tumours (AbdRaboh et al., 2013). 
Identification of the molecular characteristics of cancer of the breast allows accurate 
prediction of the path of the disease and its response to chemotherapy (Normanno et al., 
2005). The over-expression of HER1 and HER2 correlate with the poor prognosis in breast 
cancer (Uzan et al., 2009). This over-expression was associated with gene amplification of 
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HER2 in approximately 10 to 25% of invasive breast cancer and an adverse consequence 
on the course of the disease (Menard et al., 2001). 
 
SNPs are the most common source of human genetic variation that contributes to 
susceptibility to malignant alterations (www.ncbi.nlm.nih.gov, 2011). According to Wang et 
al. (2007), an SNP at codon 497 of HER1 gene causes the Arg (R) and Lys (K) 
substitution in the extracellular domain known as HER1 R497K has been identified in 
cancer of the breast. El-Mougy et al. (2012) indicated that an SNP at codon 655 of HER2 
shows an isoleucine-to-valine substitution in the trans-membrane domain which has been 
associated with the risk of breast cancer. AbdRaboh et al. (2013) found that HER1497K 
and HER2655V polymorphisms may be considered susceptibility genetic markers for the 
risk of breast cancer, but are not suitable to measure disease aggressiveness. 
 
Polymorphisms probably affect the risk of developing breast cancer by a small percentage, 
but their impact on breast cancer risk may be significantly higher than that of the relatively 
rare BRCA mutations (Fabian et al., 1996), and the combined effect of several 
polymorphisms on the risk of breast cancer could be substantial (Joy et al., 2005). 
 
Further research on genetic polymorphisms that influence breast cancer susceptibility is 
still required prior to it being useful in classifying women into risk groups for breast cancer 
(Fabian et al., 1996). 
 
2.10 Genetic counselling and testing  
Genetic education and counselling includes identifying the most informative person in the 
family to test, which may be an affected family member rather than the individual seeking 
genetic services (National Cancer Institute, 2014). In addition, counselling includes 
discussing the limitations of the test, all potential test outcomes, and the consequences of 
identifying a variant of unknown clinical significance (Riley et al., 2012). 
 
The aim of genetic counselling is to educate people about their risk and encourage 
individuals who have an increased risk of developing the disease, to develop a 
management plan (Watson et al., 1999). However, it is unclear whether or not genetic 
counselling helps to allay the fears of these women (Watson et al., 1999). Women at risk 
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of developing hereditary breast cancer feel more emotionally burdened (Lloyd et al., 1996). 
Furthermore, it is unclear whether or not women understand the information provided to 
them or are even able to use it to the benefit of their mental or physical health (Watson et 
al., 1999). 
 
Doctors are crucial in identifying women with an increased risk of developing cancer of the 
breast (de Bock et al., 2001). Providing genetic advice about cancer of the breast at the 
primary health care (PHC) level is doubtful, as women display poor compliance with the 
advice provided, poor compliance by the doctors themselves with advice given by the 
clinical geneticist, as well as the fact that no evidence is available which shows that 
surveillance is effective in females under the age of 50 (de Bock et al., 2001).   
Offering genetic testing is recommended when a risk assessment suggests the presence 
of an inherited cancer syndrome for which specific genes have been identified (National 
Cancer Institute, 2014).  
The American Society of Clinical Oncology (ASCO) (2003) and Robson et al., (2010)  
propose that genetic testing be offered when the following apply: 
• The individual has a personal or family history suggestive of a genetic cancer 
susceptibility syndrome; 
• The results of the test can be interpreted; 
• Testing will influence medical management.  
However, no such study has been conducted in the South African context. Women are 
now more accepting and open to being educated on their health.  The situation may 
therefore be quite different in the South African context, and a much higher compliance 
may be achieved. Moreover, extensive attention is given to breast cancer in South Africa, 
as the media encourages women to better understand their bodies. 
 
Genetic counselling provides individuals with information that either tells them what their 
risk is of developing the disease per year or by a certain age (Watson et al., 1999). In 
order to provide a useful service, it is imperative that people understand and utilize the 
information provided to them, as lack of understanding would not enable them to make 
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proper decisions about management of their health, as well as cause more concern over 
their health (Watson et al., 1999). 
 
Genetic testing for mutations in cancer susceptibility genes in children is particularly 
complex. While both parents (Bradbury et al., 2010) and providers (O’Neill et al., 2010) 
may request or recommend testing for minor children, many experts recommend that 
unless there is evidence that the test result will influence the medical management of the 
child or adolescent, genetic testing should be deferred until legal adulthood (age 18 years 
or older) because of concerns about autonomy, potential discrimination and possible 
psychosocial effects (Wertz et al., 1994; Nelson et al., 2001). 
 
In South Africa, diagnostic BRCA testing has been available since 2005, and has been 
facilitated by the identification of common mutations in the BRCA1 and 2 genes in both 
Afrikaner (Reeves et al., 2004; van der Merwe and van Rensburg, 2009) and other local 
populations (van der Merwe et al., 2012). This has allowed genetic counselling and 
testing to be offered, but attempts to establish programmes for genetic counselling and 
testing to stratify patients for possible genetic testing are difficult to implement in the 
South African environment and have faced many challenges, including, complexity of the 
risk assessment and testing approach; limited financial and human resources; limited 
community knowledge of breast cancer or of the possibility of a familial cancer; and 
difficulty accessing old hospital records of family members (Schoeman et al., 2013). 
 
2.11 Uptake of genetic counselling and testing 
Genetic testing entails educating women on their risk, personalized genetic information 
and providing them with recommendations for continuous risk management, which 
includes regular screening, chemoprevention and prophylactic surgical interventions 
(Bouchard et al., 2004). Genetic testing benefits women who have already had breast 
cancer as well as unaffected women within affected families (Sherman et al., 2014). 
Women who have already been diagnosed with breast cancer and found to be BRCA1/2 
carriers may consider prophylactic strategies to decrease their risk of developing a 
secondary breast cancer (Miller et al., 2006). Genetic risk information to unaffected women 
may assist in clarifying their risk status, reduce medical uncertainty, and aid with decisions 
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about risk management (Patenaude, 2005). 
 
 Genetic counselling and BRCA1 and BRCA2 gene testing are regularly offered in a 
clinical setting yet no information is available on the proportion of breast cancer patients 
who have a family history, undergoing genetic counselling (Ayme et al., 2014). Despite the 
value of genetic testing and genetic counselling for high risk breast cancer survivors, not 
much information on their uptake is available (Hamann et al., 2013).  
 
Hamann et al. (2013) found that 30.8% of the respondent survivors reported having seen a 
genetic counsellor in the period after their breast cancer diagnosis whilst 33.6% indicated 
that they had a genetic test done. Ayme et al. (2014) found a significant increase in the 
utilization of genetic counselling over time and further that patients who had a high familial 
risk had genetic counselling more often than those with an average familial risk.  
 
The most common reasons for first degree relatives of breast cancer patients wanting 
genetic testing was to learn about their children’s risk, to increase the use of cancer 
screening tests, and to take better care of themselves (Lerman et al., 1995). Lerman et al. 
(1995) found that women with a less formal education were motivated by decisions of 
childbearing and future planning compared to women who had an education beyond high 
school. 
 
2.12 Knowledge of and attitudes towards breast cancer screening and 
genetic testing  
In a study of 314 Trinidadian women, 40 years and older, to determine their breast cancer 
knowledge, attitudes and practices, Gosein et al. (2014) found that women who had a 
higher level of education had a greater knowledge about the benefits of detecting breast 
cancer at an early stage. In addition, they could further understand that an abnormal 
mammography result did not necessarily mean they had breast cancer. However, incorrect 
beliefs, especially that compression of the breast causes cancer, were found among 





An analysis of knowledge and attitudinal factors amongst African Americans associated 
with the uptake of genetic testing found positive expectations about the benefits of genetic 
testing, although participants’ knowledge on breast cancer genetics and the availability of 
genetic testing was relatively low (Halbert et al., 2005). 
 
It is important that culturally sensitive awareness campaigns take place to educate women 
who are hesitant about breast cancer screening due to perceived pain (Gosein et al., 
2014). Charles et al. (2006) found that African American women who received culturally 
modified genetic counselling were more likely to report lesser cancer-related worries 
compared to women who received standard counselling. 
 
Patenaude et al. (2013) conducted a study on daughters of BRCA1/2 mutation carriers, 
aged 18 to 24 years, on their understanding of their 50% chance of being a mutation 
carrier, their options for risk reduction or management; the extent and nature of their 
cancer-related distress, and the effect of their mothers’ mutation status on their future 
plans. The results showed that the daughters’ genetic knowledge is suboptimal with gaps 
and misconceptions being common. More than one-third of the daughters reported high 
levels of distress and indicated that the disclosure of their mothers’ genetic information 
was concern for their future, especially in terms of childbearing (Patenaude et al., 2013). 
Targeted professional attention to this high-risk group is crucial to inform the daughters of 
BRCA mutation carriers and encourage screening by the age of 25, as this could improve 
survival, and psycho-education could reduce their distress related to cancer (Patenaude et 
al., 2013). 
 
Parsa et al. (2008) found that the most common reasons women provided for not wanting 
to go for a breast cancer screening were lack of knowledge, being too busy, feeling 
embarrassed, fear of a cancer diagnosis, the cost of screening, and thinking it is not 
necessary. The study used 425 high school teachers; of the participants, 18 had a 
postgraduate degree; 376 had a degree; 23 had a diploma; and the remaining 8 had other 
qualifications. Parsa et al. (2008) concluded that the participants’ knowledge about breast 
cancer was inadequate; very few performed breast self-examinations, and most did not 




shows the importance of educating women; whether educated or not, many women still 
require further information to assist them with taking important health decisions. 
 
2.13 Risk assessment  
In order to ensure that they provide appropriate information to women about increased 
breast cancer risks, doctors need to understand what modifiable and non-modifiable 
factors contribute to these risks (Steiner et al., 2008). This will also provide women with 
the opportunity to better understand and participate more actively in their health and well 
being (Steiner et al., 2008). Risk assessment will most probably remain a crucial 
component of early detection for breast cancer (Joy et al., 2005).  
 
The aim of improving risk assessment is to classify strategies for the detection of breast 
cancer in order to increase survival and decrease cost and complications in high- and low- 
risk women, respectively (Flacke et al., 2001). 
 
There are two types of risk assessment: firstly, what a woman’s chances are of developing 
breast cancer over a specified time, which includes her lifetime, and secondly, the chances 
of having a mutation in one of the high-risk genes such as BRCA1 or BRCA2 (Gareth et 
al., 2007). 
 
Tools have been developed and are available to determine a woman’s risk. For example, 
the Tyrer-Cuzick model, which assesses breast cancer risk over time (Gareth et al., 2007) 
and the Gail model. Gail et al. (1989) used data from the Breast Cancer Detection 
Demonstration Project to develop a model to determine the absolute risk of breast cancer 
for women in a given age interval.  
 
The Gail model considers, age of the person, age at menarche, age first live birth, number 
of previous benign breast biopsy examinations, and number of first-degree relatives with 
breast cancer, in assessing the risk of breast cancer (Chen et al., 2006; Reddy Challa et 
al., 2013). The Tyrer-Cuzick model takes into consideration age, body mass index, age at 
menarche, age at first live birth, age at menopause, hormone replacement therapy use, 
breast biopsies and family history (first-degree relatives, second-degree relatives, age at 
onset of breast cancer, bilateral breast cancer and ovarian cancer) in assessing the risk of 
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breast cancer (Reddy Challa et et al., 2013). In a validation process, Amir et al. (2003) 
found that the Tyrer-Cuzick model performed by far the best at breast cancer risk 
estimation. 
 
2.14 Barriers to genetic risk assessment  
There are specific cognitive and affective factors that influence an African American 
woman’s interest in and her decision to undergo a genetic risk assessment (Sherman et 
al., 2014. These factors include their awareness of their risk in developing breast cancer, 
the level to which she approves specific limitations of undergoing genetic testing, her 
philosophical beliefs and temporal orientation, as well as her cancer-related distress. 
Furthermore, lack of knowledge and/or negative attitudes regarding genetics and genetics 
research, as well as concerns about the potential for racial discrimination were found to be 
barriers to genetic counselling and testing (Simon & Petrucelli, 2009). 
 
In a review focused primarily on systematic factors affecting uptake among minority 
populations, black, Hispanic, and Asian-Americans, Forman and Hall (2009) highlighted 
barriers such as time limitations, geographic barriers and cost, access to specialist 
services, as well as limitations of the current genetic modelling technologies. 
 
Comparisons of African-American and Caucasian women, found considerable differences 
regarding their knowledge about the genetics of breast cancer (Hughes et al., 1997; 
Donovan & Tucker, 2000;); perceptions of risk (Donovan & Tucker, 2000); support for the 
benefits and limitations of undergoing counselling and testing (Hughes et al., 1997; 
Donovan & Tucker, 2000; Thompson et al., 2003), and ability to cope with emotional 
distress associated with genetic testing (Donovan & Tucker, 2000). According to Sherman 
et al. (2014), this emphasises the need for targeted interventions to assist with decisions 
about participating in genetic counselling and testing that should be tailored to the specific 





2.15 Health Belief Model of Health Promotion as a conceptual framework 
The Health Belief Model is the most commonly used theory in health promotion and 
education with the underlying concept being that an individual’s personal beliefs or 
perceptions about a disease determine an individual’s health behaviour 
(www.jblearning.com). Four perceptions are the main constructs of the model 
(www.jblearning.com):  
• Perceived seriousness: This relates to how seriously the individual perceives the 
disease to be. 
• Perceived susceptibility: Individuals’ perceived risk or susceptibility to developing a 
disease and the role this plays in their adopting a healthier lifestyle – the greater 
they perceive their risk to be, the greater the changes of behaviour to decrease 
their risk. 
• Perceived benefits: How individuals view the usefulness of a new behaviour in 
decreasing their risk of developing a disease – people adopt new behaviours if they 
believe the new behaviour will decrease their chances of developing the disease. 
• Perceived barriers: Individuals evaluate the barriers in the way of adopting a new 
behaviour – this is the most significant construct in determining behaviour change. 
 
In addition to the original four constructs, the following were included: 
• Modifying variables: how individuals’ personal factors affect whether or not they will 
adopt the new behaviour; 
• Cues to action: factors that will initiate a change to behaviour; and 





































Figure 2.1: Health Belief Model of Health Promotion 
Adapted from www.jblearning.com; http://en.wikipedia.org  
 
Parsa et al. (2008) found that women with a perceived susceptibility or seriousness of 
breast cancer are more likely to participate in breast cancer screening, but must also view 































It is imperative to understand how South African women perceive screening and 
assessments for breast cancer. Currently such information is not available; however, 
should studies be conducted to determine this, it will assist with the development of health 
education programmes with culturally appropriate information and also provide the basis 
for the establishment of screening services in rural areas. In order to decrease mortality 
due to breast cancer, health care professionals need to understand what influences 
women’s behaviours for breast cancer screening and assessment. Health care 
professionals must further educate and inform women about the need and benefits of 
screening and assessments in order to achieve the goal of early detection in South Africa. 
 
2.16 Summary  
Breast cancer not only affects the individual who has been diagnosed, but is also a life- 
altering experience for the patient’s or survivor’s family. It is therefore essential that breast 
cancer patients and their families be provided with the necessary counselling to help them 
cope with this stressful situation. Since breast cancer can be hereditary, family members 
of patients or survivors of breast cancer should be provided with genetic counselling to 
determine their risk of developing the disease. In addition, more focus must be placed on 
raising awareness amongst women on the importance of breast self-examination, clinical 
breast examination, and mammography. Early detection is the key to saving numerous 











CHAPTER III: METHODS  
 
3.1 Introduction 
This chapter describes the research design and methodology of the study including the 
location (setting), study population, sample and sampling, data collection, management 
and analysis, and validity and reliability.  
 
3.2 Research design  
The study was a descriptive cross-sectional study and utilised quantitative and qualitative 
methods of data collection. 
 
3.3 Study location  
The study was conducted in the Msunduzi Local Municipality in KwaZulu-Natal. Msunduzi 
Municipality, which is commonly known as Pietermaritzburg, is located along the N3 and is 
considered an industrial as well as an agro-industrial corridor (IDP, 2011- 2016). 
Pietermaritzburg is the second largest city in KwaZulu-Natal and a contributor to 80% of 
the GDP by nine of the largest cities in South Africa (IDP, 2011-2016). Pietermaritzburg is 
the capital city of KwaZulu-Natal and the main economic hub with the Umgungundlovu 




Figure 3.1 Map of Msunduzi Municipality 
 Source: Pietermaritzburg Msunduzi Municipality, Integrated Development Plan (IDP) 
(2011-2016) 
 
3.4 Target population 
All females, and their spouses, from the Msunduzi Local Municipality who were diagnosed 
with, as well as survivors of breast cancer, in 2003. 
 
3.5 Study population  
The study population consisted of female breast cancer survivors who attended the 
Pietermaritzburg Cancer Association of South Africa (CANSA) support group, their 




3.6 Inclusion criteria 
The main criteria for inclusion in the study were that participants: 
• Were female breast cancer survivors from the Pietermaritzburg CANSA support 
group; 
• had biological children,  
• were above the age of twenty from the general public. 
 
In addition, the women 
• had to be from various racial groups on the CANSA support group database; 
• could be from rural or urban areas; 
• had to reside within a 40km radius of Pietermaritzburg region in KwaZulu-Natal, 
and 
• need not have a spouse (as older participants may have lost their spouses). 
 
3.7 Exclusion criteria 
Females below the age of 20 and above the age of 80 in the general public were excluded 
from participation. 
 
3.8 Sample size 
There was no sample size calculation done. All breast cancer patients enrolled within the 
Cancer Association of South Africa’s breast cancer support group, as well as selected 
family members were enrolled in the study. A convenient number of women from the 
general public were also enrolled in the study. A total of fifty-six participants were enrolled 
for the study.  
 
3.9 Selection of sample 
The researcher was advised, in 2003, that the Cancer Association of South Africa was 
running a support group for all breast cancer patients and would therefore be the ideal 
source from which to gather information on patients with breast cancer. The CANSA 
breast cancer support group did not have any black or coloured females. All patients 
requested to participate in the study consented to their participation.  
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Twenty-eight female breast cancer patients enrolled with the Pietermaritzburg CANSA 
support group; four families of breast cancer survivors, including two spouses and six 
children, and twenty females aged between 20 and 70 from the general public were 
selected as the sample for the study.  
 
3.10 Sampling technique 
Purposive and convenient sampling methods were utilized. Purposive sampling was used 
as it allowed ease of access to a number of breast cancer patients in a localized area. 
Cost considerations influenced the choice of convenient sampling as all costs for travel 
were incurred by the researcher.   
All breast cancer survivors who were part of the Pietermaritzburg CANSA support group, 
and agreed to participate, were included in the study. Twenty-eight breast cancer survivors 
consented to participate and filled in the self-administered questionnaire. 
 
Four families of the twenty-eight breast cancer survivors were then randomly selected to 
participate in a semi-structured interview with the researcher, during which time the patient 
was interviewed separately from her spouse and children. 
 
Women from the general public who worked at the South African Police Services (SAPS) 
Head Office in Pietermaritzburg, third- and fourth-year University of KwaZulu-Natal female 
students, and home executives in the Northdale area in the Msunduzi local municipality 
were approached at meetings and home visits to participate in the study.  
 
3.11 Data collection  
Quantitative and qualitative data was collected using self-administered questionnaires and 
semi-structured interviews. 
 
3.12 Data collection instruments  
Data was collected by means of two research instruments, namely self-administered 




• Self-administered questionnaires. These were administered to breast cancer 
patients and women of the general public. The questionnaire contained multiple 
choice questions, which included questions on age at menarche, age at birth of first 
live child, number of previous benign breast biopsy examinations and number of 
first-degree relatives with breast cancer, as well as open-ended questions. The 
Gail Model (Euhus, 2001) was used as a guide in developing the multiple choice 
questions for the questionnaire. The open-ended questions were designed to 
obtain further information from the multiple choice questions. 
 
• Semi-structured interviews. These were conducted with breast cancer patients and 
their family members. The questions were developed based on the information 
received from the self-administered patient questionnaires. The semi-structured 
interviews therefore served as a means of clarifying and expanding on the data 
collected from the questionnaires.   
 
The utilization of these two data-collection methods prompted the development of four 
research instruments. Each instrument was developed for one of the specific target 
groups. Out of the four measuring instruments developed, instruments I, III, and IV, 
consisted of sub-sections, for easy categorisation and analysis of data (table 3.1). 
 
















Semi-structured interview with family members of breast cancer 
patients.  
 
Instrument I: In an attempt to determine whether women seek genetic counselling 
regarding a predisposition to breast cancer, the patients were questioned about any advice 
offered to them regarding the potential risk factors of breast cancer before being 
diagnosed. Finally, patients were asked if they would have attended a breast cancer risk-
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assessment counselling session, to provide them with information about their breast 
cancer risks, screening options, as well as an option to undergo gene testing for hereditary 
cancer. The questionnaire also probed the breast cancer patients’ knowledge of 
reconstructive surgery, the success rate of reconstructive surgery, and any type of family 
counselling offered to their family. The latter question was composed to determine if any 
counselling was offered to family members of breast cancer patients to assist them in 
coping emotionally and mentally with the patients’ diagnosis. 
 
Instrument II: The questionnaire sought to determine the level of knowledge regarding 
breast cancer; whether these women conducted clinical or self-breast examinations as a 
precautionary measure and whether they would be interested in seeking genetic 
counselling and testing services. 
 
Instrument III: The semi-structured interviews focused mainly on the emotional status of 
the patient; the need to obtain more information, either medical or genetic in nature, and 
the need to obtain genetic counselling. Questions regarding counselling were asked at four 
stages: after diagnosis, before treatment, after treatment, and family attitudes. Questions 
on counselling sought answers on whether the doctor had suggested they visit or consult a 
counsellor, type of counsellor visited, and information obtained from the counsellor.  
 
Instrument IV: The questions in these interviews were designed to determine family 
members’ knowledge about breast cancer at the time of diagnosis, and whether they 
attempted to obtain additional information on breast cancer. Family members were also 
probed about genetic counselling and risks associated with breast cancer. They were 
further asked about the type of information they would have appreciated and considered 
useful from a counsellor.  
 
3.13 Data collection techniques  
3.13.1 Questionnaires 
The questionnaires were administered in two stages. The questionnaire for the women of 
the general public was administered two weeks after instrument I.  
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Instrument II was administered two weeks later as it provided the researcher with an 
opportunity to identify candidates from the general public to be included in the study and to 
obtain the necessary consent from these women.  
 
3.13.2 Semi-structured interviews 
Semi-structured interviews were scheduled with the breast cancer patients, their spouses 
and their children, so as to obtain additional information that had not been captured 
through the administration of the questionnaires. 
 
The selection of breast cancer patients for the semi-structured interviews was such that 
one woman was selected from the age groups: 30-40, 41-50, 51-60 and 61-70. This 
ensured that women were married and also had offspring. Four patients were chosen at 
random from the respondents of the initial questionnaire (instrument I). The chosen 
patients were then contacted and asked to voluntarily participate in a semi-structured 
interview. The patients were also informed that their participation would eventually require 
the participation of their spouse as well as their children in a separate semi-structured 
interview. It was therefore suggested to them that they discuss this participation in the 
semi-structured interview with their family, prior to their agreement of participation. The 
patients were given a period of one week to discuss their family’s participation in the 
interviews and were contacted to determine what decision had been taken. The patients 
were then asked to advise the researcher of the time, date and venue that would be most 
suitable for themselves, their spouses, and their children to participate in the semi-
structured interviews. The interviews were scheduled at times which participants had 
requested. This ensured the interviews did not interfere with work, school or university 
hours. No compensation was provided to participants. 
 
After verbal consent had been obtained from all the participants, final preparations for the 
interviews were made. The participants were contacted and the dates, times and venues 
were discussed and agreed upon. All the participants indicated that they felt more 
comfortable being interviewed at their homes. In instances where the children resided 
outside Pietermaritzburg, the semi-structured interviews were conducted telephonically. 
Prior to commencement of each of the semi-structured interviews, breast cancer patients, 
their spouses, and their children were advised of the purpose of the interview, that all 
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information provided by them would be treated with the strictest of confidence and that 
their participation in the interview was voluntary.   
 
At the beginning of each semi-structured interview the breast cancer patient and her 
spouse and children were informed that each interview would be conducted separately so 
as to avoid any bias of information obtained, and invasion of privacy. The semi-structured 
interviews were conducted on an informal basis at the patient’s home and this ensured a 
friendly and relaxed atmosphere.  
 
Of the 12 semi-structured interviews conducted, ten were face-to-face interviews at the 
patients’ home and two were telephonic, as the children resided outside of KwaZulu Natal. 
All semi-structured interviews were conducted in English. Notes were taken by the 
researcher during each interview. A time period of one hour was allocated for each semi-
structured interview.  
 
3.14 Design and development of the research instruments 
The research instruments were designed, after which additional improvements to the 
original instruments were made in order to develop refined instruments, which ultimately 
resulted in the final instruments used in the study.  
 
3.15 Pilot study  
A pre-test of the instruments was conducted at the University of Kwa-Zulu Natal prior to 
commencement of the study. This involved twenty-three participants, consisting of breast 
cancer survivors, as well as students from the University. The pre-test assisted with 
rectifying ambiguities and grammar in the instruments and resulted in the instruments 
being amended accordingly. The pre-test resulted in data-collection instruments that were 
understood by both the researcher and the sampled respondents, providing confidence 
and satisfaction that the instruments met the acceptable standards of reliability and 






3.16 Reliability and validity  
The quality of research is determined by its validity and reliability (De Vos et al., 2005). 
Reliability refers to the extent to which results can provide accurate representation of the 
total population over time while validity determines whether the research instrument 
properly measures what it is intended to measure. Pre-testing the instruments in the pilot 
study resulted in clarification and ensured acceptable standards of validity and reliability. 
 
3.17 Data management 
All data received at each stage of the study was captured electronically within a week of 
receipt and hard copies filed as a back-up. At the end of data capturing, data verification 
was done by the researcher to avoid any duplication or double entry of data captured. 
 
3.18 Data analysis 
Descriptive analysis was conducted on the data. The data was summarised. Continuous 
numerical data was summarised using measures of central tendency such as means and 
medians. Categorical data were summarised in proportions and displayed graphically in 
pie charts or bar graphs.   
 
The raw data obtained from instrument III and IV was organised into conceptual 
categories, and themes or concepts were created to analyse the data. 
 
3.19 Application and variables measured 
3.19.1 Instrument I: Self-administered questionnaire for breast cancer 
patients 
The questionnaire measured the following variables: 
 biographical data: age, race, weight and height of the patient 
 data on lifestyle before diagnosis: smoking habits, alcohol intake per day, number of 
servings of vegetables per day, and amount of radiation they had been exposed to in the 
past 




3.19.2 Instrument II: Self-administered questionnaire for women from the 
general public 
The questionnaire measured the following variables: 
 age 
 racial group  
 family history of breast cancer 
 lifestyle  
 knowledge of breast cancer  
 uptake of genetic counselling or risk assessment 
 
3.19.3 Instrument III: Semi-structured interview with breast cancer patient 
The interview covered: 
 provision of counselling  
 risk calculations for family members 
 
3.19.4 Instrument IV: Semi-structured interview with family members of 
breast cancer patients 
The interview covered: 
 children’s and spouse’s understanding of breast cancer 
 views about breast cancer 
 information on breast cancer obtained after diagnosis 
 uptake of genetic counselling or risk assessment by the children of breast cancer 
survivors  
 knowledge of breast cancer at the time of diagnosis 
 knowledge of associated risks 
 methods of primary prevention and early detection of breast cancer. 
 
3.20 Quality assurance 
The researcher monitored all the processes involved in planning and conducting this 
study. The researcher took full responsibility in developing and conducting the research, 




Procedures and methods followed were fully documented. All processes were transparent 
in obtaining and capturing of the data obtained and all research data obtained from the 
questionnaires and semi-structured interviews confidentially filed. 
 
3.21 Researcher’s role in the study  
The researcher’s role was to facilitate, as an “outside agent”, the administering of the 
questionnaires and conducting of the semi-structured interviews without any bias, and to 
further capture and report all results as reported by participants in the study.  
 
3.22 Ethics and informed consent 
Ethical approval was waivered by the Dean of Science and Agriculture, Professor D. 
Jaganyi, due to the fact that when this study was conducted, the amendment to the 
National Health Act (Act 61 of 2003) was not affected. Hence, obtaining ethical approval 
from an Ethics Committee was, at the time of this study, not required. 
A covering letter accompanied each questionnaire, indicating the purpose of the study, 
that participation was voluntary and assuring the participant of confidentiality. Prior to each 
interview, the researcher explained the purpose of the study, the voluntary basis of 
participation and the assurance of confidentiality. Informed verbal consent to participate 
was received from each participant before commencing the interview.  
 
3.23  Data collection  
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3.24 Summary  
This chapter discussed the research design and methodology, including the development, 
pre-test, reliability and validity of the data-collection instruments, data management and 
analysis, and ethical considerations. The whole process afforded the researcher the 





CHAPTER IV: RESULTS 
 
4.1 Introduction 
This chapter describes the interpretation and explanation of the findings of the study in line 
with the research questions and objectives of the study. The results are discussed under 
the following subtopics: socio demographic profile of the study population, racial profile of 
the study population; risk factors for developing breast cancer; surviving breast cancer 
patient therapy; genetic counselling - awareness and practice of breast cancer survivors 




4.2.1 Biographical, medical and lifestyle profiles 
4.2.1.1 Profile of study participants 
Twenty-eight female breast cancer patients and twenty females from the general public 
responded to questionnaires. Four breast cancer patients; two spouses and six children 
were interviewed (table 4.1)  
Table 4.1: Frequency distribution of respondents for each of the instruments (2003) 
Study population Instrument Number 
responded 
Percentage 
Breast cancer patients I 





Women from the 
general public 
 
II 20 35.7% 
Children 
 
IV 6 10.7% 
Spouses 
 
IV 2 3.6% 






4.2.1.2 Participants’ age profile  
Patients diagnosed with breast cancer were aged between 34 and 75 years of age, and 
the women from the general public were aged between 21 and 70 years. The majority 
(n=43 or 89.6%) of the respondents were 30 to 70 years old (table 4.2).  
Table 4.2: Frequency distribution of participants’ age groups (2003) 











21-30 Nil (0%) 5 (25%) 5 (10.4%) 
31-40 4 (14.3%) 9 (45%) 13 (27.1%) 
41-50 5 (17.9%) 5 (25%) 10 (20.8%) 
51-60 4 (14.3%) Nil (0%) 4 (8.3%) 
61-70 7 (25%) 1 (5%) 8 (16.7%) 
71-80 8 (28.6%) Nil (0%) 8 (16.7%) 
Total 28 (100%) 20 (100%) 48 (100%) 
 
 
4.2.1.3 Patients’ age at first breast cancer diagnosis 
Of the respondents, 35.7% (n=10) were in the 61 to 70 year age group when diagnosed 
with breast cancer; 25% (n=7) were in the 41 to 50 year age group; 21.4% (n=6) were in 
the 51-60 year age group; 14.3% (n=4) were in the 30 to 40 year age group, and only 
3.6% (n=1) in the 71-80 year age group (table 4.3).  
Table 4.3: Frequency distribution of age at first diagnosis (2003) 
 Age group Number of patients Percentage 
30-40 4 14.3% 
41-50 7 25% 
51-60 6 21.4% 
61-70 10 35.7% 
71-80 1 3.6% 




4.2.1.4 Participants’ gender profile  
Of the study population participants, 94.6% (n=53) were female and only 5.4% (n=3) were 
males (figure 4.1). The female participants included working class women (n=34), females 
who were studying (n=5), as well as home executives (n=14). Of the three male 
respondents, two were spouses and one was the biological son of the breast cancer 
patient. The spouses (n=2) were employed and the son (n=1) is a student. 
 
 
Figure 4.1: Participants’ gender distribution (2003) 
 
 
4.2.1.5 Participants’ racial profile  
Breast cancer patients from two of the four major South African racial groups, namely 
Indian and White, responded to instrument I; whilst Black, Indian and White women from 
the general public responded to instrument II. One Indian and one White spouse were 
interviewed, and of the six children interviewed, four were white females and two Indian 











Figure 4.2: Participants’ racial profile  
 
4.2.2 Risk factors which may contribute to the development of breast cancer 
4.2.2.1 Patients perspective 
Of the twenty-eight breast cancer patients, 28.5% (n=8) noted that only one of the factors 
listed affected them in some way, while 3.5% (n=1) noted that none of the factors listed 
affected her in any way. 
 
Ten of the twenty-eight breast cancer patients, 35.7% (n=10) noted that two of the seven 
factors affected them as follows: 50% (n=5) indicated early menstruation and early live 
birth; 20% (n=2) indicated early menstruation and alcohol; 10% (n=1) indicated smoking 
and early live birth; 10% (n=1) indicated alcohol and radiation, and 10% (n=1) indicated 
early menstruation and oestrogen contraceptives. Twenty three (82%) of the patients 
identified early menstruation as a factor that could probably have contributed to the 














Table 4.4: Frequency distribution of risk factors which may have contributed to the 
development of breast cancer according to breast cancer patients (2003) 




Alcohol 8 11.9% 
Smoking 3 4.5% 
Radiation 2  3% 
Early menstruation (<15 years of 
age) 
23 34.3% 
Early live birth (<24 years of age) 16 23.9% 
Late live birth (>25 years of age) 11 16.4% 
Oestrogen contraceptives 4  6% 
 
 
4.2.2.2 General public perspective 
Of the twenty respondents from the general population, 10% (n=2) noted that none of the 
factors listed affected them in any way and 25% (n=5) noted that only one of the factors 
listed affected them in some way.  Ten respondents (50%) noted that two of the seven 
factors affected them as follows: 80% (n=8) indicated early menstruation and early live 
birth, and 20% (n=2) indicated early menstruation and oestrogen contraceptives.  
 
Three respondents, (15%), noted that three of the seven factors affected them as follows: 
66.7% (n=2) indicated early live birth, early menstruation and oestrogen contraceptives, 
and 33.3% (n=1) indicated smoking, early live birth and early menstruation.  
 
Fifteen of the twenty respondents from the general public, 75% noted early menstruation 





Table 4.5: Frequency distribution of risk factors which may contribute to the development 
of breast cancer according to women from the general public (2003) 






Alcohol Nil  0% 
Smoking 1  2.9% 
Radiation Nil 0% 
Early menstruation (<15 years of age) 15  44.1% 
Early live birth (<24 years of age) 14  41.1% 
Late live birth (>25 years of age) Nil  0% 
Oestrogen contraceptives 4 11.8% 
 
 
4.2.3 Common symptoms, survival and therapy for breast cancer patients 
4.2.3.1 Common symptoms before breast cancer diagnosis 
The majority of the patients, (67.9%; n=19) experienced a lump or thickening in the breast 
or armpit, which led to a positive diagnosis of breast cancer while 14.3% (n=4) 
experienced none. One patient, (3.6%) had a combination of two symptoms, namely a 
lump or thickening in the breast or armpit as well as changes around the nipple. 
 
A combination of three symptoms was experienced by 7.1% (n=2) of the patients; one 
patient experienced a lump or thickening in the breast or armpit, together with changes 
around the nipple and changes in size or shape of the breast, and the other patient 







Table 4.6: Frequency distribution of patients’ most common symptoms before diagnosis 
(2003) 
Symptoms Number of patients Percentage 
Lump or thickening in the breast 
or armpit 
19 67.9% 
Changes in the skin – dimpling, 
puckering or redness 
3 10.7% 
Changes in the nipple – direction 
of the nipple or an unusual 
discharge 
3 10.7% 
Changes around the nipple – 
unusual rash or sore area 
2 7.1% 
Changes in the size or shape of 
the breast 
2 7.1% 
None 4 14.3% 
 
 
4.2.3.2 Years of survival after breast cancer diagnosis 
The majority of patients, 57.1% (n =16), had survived between 0 and 5 years after being 
diagnosed with breast cancer, whilst 28.6% had survived for between 6 and 10 years and 
14.3% of patients had survived between 11 and 15 years after the diagnosis. At the time of 
the study four patients were between the ages of 30 and 40, seven patients were between 
the ages of 41 and 50, seven patients were between the ages of 51 and 60, nine patients 
were between the ages of 61 and 70 and only one patient was 77 at the time of diagnosis 
(table 4.7). 
Table 4.7: Frequency distribution of years of survival after breast cancer diagnosis (2003) 
Number of years Number of patients Percentage 
0-5 16 57.1% 
6-10 8 28.6% 





4.2.3.3 Surviving breast cancer patient therapy 
Only one (3.6%) of the 28 patients underwent chemotherapy alone, whilst 12 (42.9%) of 
the 28 patients did not have chemotherapy or radiation therapy and opted for surgery. 
Seven (25%) of the 28 patients underwent chemotherapy and surgery, whilst eight (28.6%) 
patients opted to have chemotherapy, radiation therapy as well as surgery (table 4.8). 
Table 4.8: Frequency distribution of type of therapy breast cancer patients underwent 
(2003) 
Type of therapy Number of patients Percentage 
Chemotherapy 1 3.6% 
Surgery 12 42.9% 
Chemotherapy + Surgery 7 25% 
Chemotherapy + Radiation therapy + 
Surgery 
8 28.6% 
Total 28 100% 
 
 
4.2.4 Knowledge about breast cancer and provision of counselling 
4.2.4.1 Level of knowledge amongst participants about breast cancer 
4.2.4.1.1 Knowledge of breast cancer  
Nine patients (32%) indicated they were unsure about the causes of their breast cancer; 
five patients (18%) attributed the cause of their breast cancer to hormone replacement 
therapy; three patients (10.7%) attributed the cause of their breast cancer to stress; two 
patients each (7%) to a sports injury and hereditary; and one patient each to smoking, 
insufficient exercise, environmental pollution, rapid cell change and post natal depression. 
One patient attributed the cause of their breast cancer to two causes (stress and heredity); 
and a further patient listed four causes (stress, hormone replacement therapy, 
environmental pollution and insufficient exercise) as reasons for the development of her 





Figure 4.3: Most likely causes of breast cancer according to breast cancer patient in 
the Msunduzi Municipality (2003) 
 
4.2.4.1.2 Participants’ interest in attending a risk assessment session 
Twenty-one study participants (43.8%, n=21) indicated they were not interested in 
attending a risk assessment session; 35.4% n=17 showed their interest in attending such a 
session; whilst 20.8% n=10 indicated they were unsure (table 4.9).  
 
Within the breast cancer patients eleven of the twenty eight breast cancer patients (39.3%, 
n=11) indicated that they would have been interested in sending their daughters for a risk 
assessment after their diagnosis, twelve patients (42.3%, n=12) indicated that neither them 
nor any of their immediate family members were interested, and 17.9% (n=5) were unsure 
about having a risk assessment done, either for themselves or their family. 
 
In the general population 45% (n=9) of respondents indicated that they would not be 
interested in attending a risk assessment session. One of these nine respondents who 
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that whilst she may not be interested at present, should the need arise for such an 
assessment in future, she will definitely go. Thirty percent of respondents (n=6) indicated 
their interest in attending a risk assessment session whilst 25% (n=5) of respondents said 
they were unsure. Twenty percent of the participants (n=1) who indicated she was unsure, 
further clarified that she would need to know what type of service a genetic counsellor 
offered prior to going to one.  
Table 4.9: Frequency distribution of study participants’ interest in attending a risk 



















Attended  Nil Nil Nil Nil (0%) 
Interested in 
attending  
11 (39.3%) 6 (30%) 17 (35.4%) 17 (35.4%) 
Not interested in 
attending (after 
diagnosis) 
12 (42.9%) 9 (45%) 21 (43.8%) 21 (43.8%) 
Unsure 5 (17.9%) 5 (25%) 10 (20.8%) 10 (20.8%) 
Total 28 20 48 100% 
 
 
4.2.4.1.3 Advice on breast cancer risk factors 
Fourteen (50%) people had received advice on risk factors for breast cancer. Of these, 
nine (64.3%) indicated that they had received this advice through the media; either through 
reading magazine articles, pamphlets or through advertisements. Four of the fourteen 
(28.6%) patients indicated that they had received advice on breast cancer risk factors from 
their general practitioner (GP) or gynaecologist. Only one (7.1%) patient indicated that she 






Table 4.10: Frequency distribution of patients who were either advised or not advised 
about breast cancer risk factors prior to diagnosis (2003) 




Percentage Advised by 
Advised prior to 
diagnosis 
14 50% Media (64.3%) 
GP/Gynaecologist (28.6%) 





14 50%  
 
 
4.2.4.1.4 Advice on factors that reduce the risk of recurrence of breast cancer 
Seventeen patients (60.7%) were advised on factors that reduce the risk of developing 
breast cancer. Of the four patients in the 30 to 40 year age group, only one patient 
indicated that she was offered advice; four of the five patients in the 41 to 50 year age 
group, three patients each in the 51 to 60 and 61 to 70 year age group and six patients in 
the 71 to 80 year age group indicated that they were offered advice (figure 4.4).  
 
These figures indicate that 80 percent of the 41 to 50, and 75 percent each in the 51 to 60 
and 71 to 80 year age groups were offered advice. Only 42 and 25 percent of the 61 to 70 
and 30 to 40 year age groups, respectively, were advised on these factors. 
 











4.2.4.1.5 Advisor on reduction of risk factors related to breast cancer 
recurrence 
Eleven patients (39.3%) indicated they had not received any advice on reduction of risk 
factors related to the recurrence of breast cancer. Eight patients (25%) indicated that they 
had been advised by a medical doctor alone; six (21.4%) patients indicated that they had 
been advised by a person not listed in Table 4.11; three (10.7%) patients indicated that 
they were each advised by a medical doctor and a person not listed; medical doctor and 
medical nurse; and medical doctor and a social worker. One (3.6%) patient indicated that 
she had been advised by a medical doctor, social worker and a dietician advised them; 
another patient (3.6%) indicated that a psychologist, medical doctor, medical nurse and a 
dietician advised her; and one patient (3.6%) indicated that a psychologist alone advised 
her. None of the 28 patients were counselled by a genetic counsellor. 
 
Only one of the seven patients indicated that they were advised by various speakers who 
were called to present during support group meetings. The other six patients did not 
indicate who they had been advised by. 
Table 4.11: Frequency distribution depicting advisor on the reduction of risk factors related 
to the recurrence of breast cancer (2003) 
Advisor Number of 
patients 
Percentage 
Medical doctor 7 25% 
Other  6 21.4% 
Medical doctor + other 1 3.6% 
Medical doctor + medical nurse 1 3.6% 
Medical doctor + social worker 1 3.6% 
Medical doctor + social worker + 
dietician 
1 3.6% 
Psychologist + medical doctor + medical 
nurse + dietician 
1 3.6% 
Psychologist 1 3.6% 
None 9 32.1% 
Genetic counsellor Nil 0% 




4.2.4.1.6 Link between advice on risk of recurrence and patient’s opinion on 
causes of their breast cancer 
Of the eleven patients recorded as not being advised about the risk for reducing breast 
cancer, seven were unsure as to the causes of their breast cancer. Of the remaining four 
patients who were not advised about the risk for reducing breast cancer, one patient 
indicated that she thought it was due to a sport injury but was not quite sure; another 
indicated that she thought it is hereditary as a number of her relatives have had breast 
cancer, the third patient indicated that she was told that her cells were changing rapidly 
and the fourth patient indicated that she thought it was due to her post-natal depression 
when she had a very stressful life (Table 4.12). 
 
Table 4.12: Frequency distribution of link between advice on breast cancer risk factors and 
patients’ opinion as to the causes of their breast cancer (2003) 
















on risk factors 




Stress 6 6  6 (18.8%) 
Post-natal depression 1  1 1 (3.1%) 
Rapid cell change 1  1 1 (3.1%) 
Hereditary 3 2 1 3 (9.4%) 
Hormone replacement 
therapy 
6 6  6 (18.8%) 
Environmental pollution 2 2  2 (6.3%) 
Insufficient exercise 1 1  1 (3.1%) 
Smoking  1 1  1 (3.1%) 
Sport injury 2 1 1 2 (6.3%) 




4.2.4.2 Genetic counselling and risk assessment 
4.2.4.2.1 Counselling opportunities provided for families of breast cancer 
patients 
Only five of the twenty-eight (17.9%) patient’s families were given the opportunity to be 
counselled after the diagnosis. Two of the five patients were between the ages of 41 and 
50 and one patient each in the 51 to 60, 61 to 70 and 71 to 80 age groups (figure 4.5).  
 
Only two of the five patients indicated who counselled their families; one patient indicated 
that a medical doctor had counselled her family and the other indicated that her oncologist 
had counselled her family. Both these patients were in the 41 to 50 year age group. 
 
 
Figure 4.5: Counselling opportunities provided to families of breast cancer patients (2003) 
 
 
4.2.4.2.2 Provision of counselling  
At the time of diagnosis only one patient was counselled and three were not.  Although 
counselling was provided to one patient at the time of diagnosis, she had indicated that no 
counselling was given on the genetics and risks involved with breast cancer. She further 
indicated that she was not satisfied with the information the psychologist had offered, and 
considered information on the genetics, recurrence, prognosis and family risk to be 














The three patients who were not provided with counselling at the time of diagnosis 
mentioned that even though they had not been counselled they would have found 
counselling on the genetics and risks of breast cancer very useful. Of these three patients 
one patient mentioned that she was quite comfortable with her doctor, one patient said that 
she would have liked to consult with an oncologist and the other patient said that she 
would have liked to meet with a person who went through a similar experience as she did. 
             
During the period before surgery two of the four patients indicated they had been 
counselled, one by a plastic surgeon and one by a surgeon. The patient counselled by the 
surgeon was presented with two options, to have a mastectomy or, to continue with 
chemotherapy and radiation therapy. The patient counselled by the plastic surgeon was 
given information on reconstructive surgery.  
 
Of the two patients who were not counselled, one said that she would not have wanted to 
consult with a counsellor and the other patient indicated that although she did not consider 
counselling, she thought that family counselling for trauma would have assisted in easing 
the pain. She further felt that the views of an oncologist, as well as information on the 
advantages and disadvantages of lumpectomy should have been provided. In addition, the 
patient indicated that by her not being provided with this information she felt the surgeon 
had denied her of her right to information. 
 
During the period after surgery only one patient was counselled by the Reach for Recovery 
breast cancer support group. This is the patient who indicated before surgery that she did 
not want to be counselled and mentioned that she found it “helpful to talk to people who 
have been through the same situation”.  
 
One of the three patients who were not counselled after surgery reiterated that although 
she did not have any counselling, she thought that family counselling would have helped. 
The other two patients stated that even though they were counselled before surgery, they 
were of the opinion that counselling provided by an appropriate counsellor rather than a 
surgeon and plastic surgeon would have helped them cope better with their mastectomy 
(Table 4.13).  
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Table 4.13: Provision of counselling to the patient at various stages (2003) 





Not provided with 
counselling 
Type of counsellor 
At diagnosis 1 (25%) 3 (75%) Psychologist 
 
Before surgery 2 (50%) 2 (50%) Surgeon;  
Plastic Surgeon 
 




4.2.5 Genetic counselling, risks, risk assessment, awareness and education 
for family members of breast cancer patients 
4.2.5.1 Genetic counselling, risks and risk assessment 
Six of the eight respondents indicated they had not been for genetic counselling and were 
not counselled on the risks associated with the development of breast cancer. Of the six, 
two respondents indicated that although they did not receive genetic counselling or 
information on the risks associated with breast cancer, they were of the opinion that such 
information would have been very valuable.  
The remaining two respondents indicated that they had been for genetic counselling and 
have been informed about the risks associated with the development of breast cancer. 
This assisted them in understanding how they could be affected by breast cancer. 
 
In terms of the risk assessment, four of the eight respondents indicated that they were not 
interested in attending a breast cancer risk assessment. However, one of these four 
respondents indicated that she might consider a risk assessment at a later stage. The 
remaining four respondents showed their interest in attending a risk assessment. 
 
4.2.5.2 Precautionary measures, creating awareness and educating family 
members on breast cancer 
Five of the respondents were females and two of the five indicated that they have not 
taken any precautionary measures. One of the three remaining females responded saying 
that she is now consuming more soya and will not take any hormone pills; the second and 
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third indicated that they were now going for regular check-ups, whilst the third respondent 
further added that she was also going for regular mammograms.  
 
In terms of creating awareness, seven of the eight respondents were of the opinion that 
enough was being done. However, in terms of educating families of breast cancer patients, 
half of the respondents (four) believed that enough was being done whilst the other half 
thought that not enough was being done to educate family members of breast cancer 
patients (Table 4.14). 













1  Not enough being 
done 
Not enough being 
done 
2 Yes Enough being done Enough being done 
3  Enough being done Enough being done 
4 Yes Enough being done Enough being done 
5  Enough being done Not enough being 
done 
6 No Enough being done Not enough being 
done 
7 No Enough being done Enough being done 




This chapter provides a detailed overview of the results of the study indicating that there is 
a lack of education and awareness about genetic counselling and risk assessment. 
Women from the general public may have basic knowledge about breast cancer but do not 
know about the genetic services available. Likewise, there is very little, if any, emphasis 
placed on the families of breast cancer patients. Appropriate counselling to assist them 
with understanding and accepting the diagnosis as well as the provision of appropriate 
information on the genetics of breast cancer, genetic counselling availability and risk 




CHAPTER V: DISCUSSION  
 
5.1 Introduction  
This chapter presents the data interpretation and explains the findings in line with the 
research questions and objectives of the study while at the same time making 
comparisons with findings of similar studies that have been conducted in other settings. 
The results are discussed under the following subtopics: biographical, medical and lifestyle 
profiles of the study participants; knowledge, awareness and practice; and genetic 
counselling, risk assessment, awareness and education for family members of breast 
cancer patients.  
 
5.2 Findings  
The key findings of this study show that participants identified that early menstruation (<15 
years of age), early first pregnancy,  before the age of 24 years were noted as  major risk 
factors  for the development of breast cancer. A lump or thickening in the breast or armpit 
prior to diagnosis was the most common symptom or sign of breast cancer, with surgery 
being the most common modality of treatment.  
 
Of the eight family members interviewed, four family members (50%) indicated that they 
were not offered genetic counselling and would not be interested in knowing about the 
risks associated with breast cancer. Of the remaining four, two (25%) indicated that 
although they were not offered genetic counselling they would be interested in genetic 
counselling and learning about the risks associated with breast cancer as such information 
would be of great value. 
 
In terms of a breast cancer risk assessment, four of the eight family members (50%) 
indicated they were not interested, with one further explaining that she might be interested 
at a later stage. The remaining four family members (50%) indicated their interest in 




Five of the eight family member (62.5%) interviewed were females. Three females (60%) 
indicated they were taking precautionary measures by going for regular check-ups and 
mammograms, consuming more soya and not taking any precautionary measures. 
Seven of the eight family members (87.5%) indicated that they thought enough was being 
done to create awareness on breast cancer; whilst four family members (50%) were of the 
opinion that not enough was being done to educate family members of breast cancer 
patients. 
The study found that the participant breast cancer patients were not informed about the 
availability of genetic counselling and testing and neither were their family members. 
Besides genetic counselling, family members, together with the breast cancer patient, 
were not appropriately counselled or provided with the option of having a risk assessment 
done. The health care professionals did not seem to be providing relevant information to 
the patients and their family, which would assist both the patient and the family in making 
informed decisions about prevention and early detection for their children.  
 
5.2.1 Biographical, medical and lifestyle profiles  
5.2.1.1 Participants’ age and racial profile  
Approximately 54% (n=15) of the breast surviving patients were between 51 and 80 years 
of age. Anecdotal evidence provided by the chairperson of the support group indicated that 
a number of young female breast cancer survivors were working women and mothers. 
Their career and family did not allow them sufficient time to be involved in the cancer 
support group. However, older women had more time available and attendance at the 
support group sessions provided them with a sense of fulfilment to assist other female 
breast cancer patients cope with their breast cancer. 
 
The majority of patients in this study were White, whilst two were Indian and none were 
Black. This was in keeping with the available information in the National Cancer Registry 






According to the National Cancer Registry Report (2014), breast cancer was the most 
commonly diagnosed cancer in all females, accounting for 21.02% of all cancers 
diagnosed with an age-specific incidence rate of newly diagnosed cases in Whites being 
54.74 per 100 000, and 15.87 per 100 000 for Black females. 
 
5.2.1.2 Age at first breast cancer diagnosis  
According to Buckman (1997), a woman’s chances of developing breast cancer increases 
with age; it is rare before the thirties, begins to increase in incidence in the forties, and 
becomes more common in the fifties and over. The findings of this study, which found that 
60.7% (n=17) were over the age of 50 at the time of being diagnosed with breast cancer; 
concur with Forbes (1997) who found that developing breast cancer increased with age, 
thereby making age the most important risk factor for breast cancer. 
 
However, even though a woman’s chances of developing breast cancer increases with 
age, the impact of developing breast cancer at a younger age is probably more difficult for 
a younger woman to accept and deal with than women over the age of 50. Avis et al. 
(2005) found that younger breast cancer survivors are at risk for impaired quality of life for 
several years after diagnosis and may need interventions that specifically target their 
needs related to menopausal symptoms and problems with relationships and body image.  
 
5.2.1.3 Risk factors which may contribute to the development of breast 
cancer according to participants 
The breast cancer patients noted a variety of risk factors that may have contributed to 
them developing breast cancer. Of the twenty-eight patients, 82% (n=23) noted early 
menstruation (<15 years of age) and 57% (n=16) noted early live birth (<24 years of age) 
as the main risk factors to the development of breast cancer. Of the twenty women from 
the general population, 75% (n=15) noted early menstruation and 41.1% (n=14) indicated 
early live birth (<24 years of age) as a factor that could probably contribute to their 
development of breast cancer. This contrasted with Kelsey et al. (1993) who found that 




Of the 28 breast cancer patients, 29% (n=8) indicated that alcohol may have contributed to 
their development of breast cancer, whilst 10.7% (n=3) indicated that they were of the 
opinion that smoking may have contributed to their development of breast cancer. Brown 
et al. (2009) found that low alcohol intake is not related to increased breast cancer risk in 
Asian-American women and that neither alcohol nor cigarette use contributed to the 
elevated risks in Asian-American women. Over the years smoking has been postulated to 
increase the risk of breast cancer (Brown et al., 2009); however, whilst many 
epidemiological studies have not supported an overall association, there are still 
unanswered questions regarding the influence of early initiation and long duration (Terry, 
2002; Ahern et al., 2009). 
 
Interestingly, none of the patients noted family history as a risk factor which may have 
contributed to the development of their breast cancer. None of the women from the 
general public had identified family history as a risk factor. 
 
5.2.1.4 Most common symptoms before breast cancer diagnosis 
Aiello et al. (2004) found that the presence of a lump was associated with a two- to three-
fold greater risk of breast cancer with and without the presence of any other symptoms in 
postmenopausal women. In our study 67% (n=19) indicated that they had a lump or 
thickening in the breast or armpit, which led to a positive diagnosis of breast cancer. Aiello 
et al. (2004), therefore suggest that a reported lump must be fully evaluated and reassure 
physicians that careful observation of women with nipple discharge and pain may be 
justified. 
 
5.2.1.5 Years of survival after breast cancer diagnosis  
The National Cancer Institute estimates that approximately 2.6 million US women with a 
history of breast cancer were alive in January 2008, more than half of whom were 
diagnosed less than 10 years earlier (American Cancer Society, 2011). Allen et al. (2009) 
attribute the rising numbers of women surviving and living with breast cancer for longer 
periods of time to improved methods of early detection and treatment. Burstein and Winer 
(2000) indicate that ninety-one percent of women diagnosed annually with breast cancer 
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will survive more than five years. The results of this study show that 42% (n=12) have 
survived between 6 and 15 years after being diagnosed with breast cancer. 
 
5.2.1.6 Advice on the advantages and disadvantages of breast cancer 
therapy 
The patient and physician often decide on an appropriate treatment option together for the 
patient after taking into consideration a number of factors, such as the biological 
characteristics and stage of the cancer, the patient’s age and preferences, as well as the 
risks and benefits related to each treatment protocol (American Cancer Society, 2011). 
However, most breast cancer patients will undergo surgery which is often combined with 
other methods of treatment such as radiation therapy, hormone therapy, chemotherapy 
and/or targeted therapy (American Cancer Society, 2011). 
 
A woman who chooses lumpectomy and radiation will have the same expected long-term 
survival as if she had chosen mastectomy; however, there is a higher risk of local 
recurrence (cancer returning to the breast) with lumpectomy (Jatoi & Proschan, 2005). The 
manner in which radiation therapy is given is dependent on the type, stage and the area in 
which the tumour is located (American Cancer Society, 2011). Accurate targeting of 
radiation therapy has radically increased in the past few years resulting in fewer side 
effects and a reduction in treatment time (Beitsch et al., 2011). Women who have 
metastatic breast cancer and who may not qualify for surgery due to the wide spread of 
the cancer, would qualify for systemic therapy as their foremost treatment option 
(American Cancer Society, 2011). 
 
In a study on breast cancer patients 70 years and older, Wang et al. (2011) found that 
surgery was performed in the majority of these patients, with approximately 50% 
undergoing lumpectomy and 50% undergoing a mastectomy. Adjuvant therapies were 
frequently excluded, with only hormonal therapy being the most commonly used. The 





In this study 57% (n=16) of the breast cancer survivors chose to have a mastectomy after 
being diagnosed with breast cancer. Only one patient had bilateral breast cancer, resulting 
in the patient having a total mastectomy on the right side and a radical mastectomy on the 
left side. Paci et al. (2002) reported that there had been a change in rates of radical 
surgery and incidence of breast cancer since the introduction of the Florence 
mammographic screening programme. The rates of breast conserving surgery in women 
aged 50-69 were 1.18 per thousand in 1990 and increased to 1.87 per thousand in 1996, 
whilst the rates of mastectomy decreased from 1.08 to 0.62 per thousand from 1990 to 
1996 (Paci et al.,2002). The researcher is of the opinion that such a screening programme 
may be beneficial to the South African population, particularly since breast cancer was the 
leading cancer in females in South Africa in 1999, with 19.36% of females being 
diagnosed with the disease (Mqoqi et al., 2004). 
 
5.2.2 Knowledge about breast cancer and provision of counselling 
5.2.2.1 Cause of breast cancer according to patient 
According to Chalmers et al. (1996), women may develop perceptions of vulnerability from 
a lived experience of cancer and through strong identification with an affected or deceased 
mother or sister. This would cause them to judge an experience that is cognitively 
available as more likely to occur, and beliefs about the frequency of lethal events may lead 
to an overestimation of risk of disease occurrence or of the seriousness of risk (Hopwood, 
2000).  In keeping with this, Offit and Brown (1994) found that women who had strong 
family histories might admit to being at an increased risk, but often thought in non-
Mendelian terms and were more influenced by their particular familial experience of the 
condition. Of the breast cancer patients, 21.4% (n=6) listed stress as the most likely cause 
for the development of their breast cancer; a further 21.4% (n=6) listed hormone 
replacement therapy. 
 
Of the patients, 7.1% (n=2), whose sisters had developed breast cancer, considered their 
breast cancer as hereditary. Koehly et al. (2008) reported that significant within-family 
correlation was found for breast cancer risk and worry, suggesting that sisters perceived a 




5.2.2.2 Participants’ interest in attending a risk assessment session  
A Canadian study conducted by Bottorff et al. (2002) found that the two most frequent 
reasons women gave for being interested in genetic testing for breast cancer risk were 
“curiosity” and “to warn family.”  Other frequently reported reasons were “to take 
preventive action”, “to achieve peace of mind” and “to reduce worry” (Bottorff et al., 2002). 
 
This study has found that 39.3% (n=11) indicated their interest in sending their daughters 
for a risk assessment.  
 
Bottorff et al. (2002) further showed that women expressed interest in genetic testing for 
breast cancer.  The percentage of women interested in genetic testing is estimated to 
range from 43 to 89%, with interest being higher in younger women and women with a 
diagnosis of breast cancer (Bottorff et al., 2002). The current study concurs with this in that 
30% (n=6) aged between 21 and 40 years indicated interest in having breast cancer risk 
assessment. 
 
5.2.2.3 Advice on breast cancer risk factors prior to breast cancer diagnosis  
In a study amongst UK women, Grunfeld et al. (2005) found that although women had a 
good understanding of certain aspects of breast cancer, there were variations in 
knowledge of risk and the various symptoms related to breast cancer. Older women were 
particularly poor at identifying symptoms of breast cancer, risk factors associated with 
breast cancer and their personal risk of developing the disease. The inferior knowledge of 
symptoms and risks among older women could probably clarify the strong correlation 
between older age and delay in seeking healthcare (Grunfeld et al., 2005). 
 
5.2.2.4 Advice and advisor on the reduction of risk factors related to the 
recurrence of breast cancer 
According to Manuel et al. (2007), younger women show greater psychological morbidity 
than older women after a breast cancer diagnosis. Manuel et al. (2007) suggest that 
clinicians should identify patients’ particular stressors and help with advice on coping 
techniques targeting particular concerns, one being social support, which is helpful in 
dealing with anger or depression. 
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One of the coping techniques is providing the opportunity for counselling. In this study only 
18% of the target group had the opportunity for family counselling. Every patient should be 
offered the opportunity to undergo counselling, whether it is for herself or her family. It 
should be the responsibility of the doctor who diagnosis her breast cancer to provide her 
with this information. However, this information about counselling should be suggested 
and not forced upon the patient. By equipping the patient with relevant information at the 
time of diagnosis, enables the patient to be knowledgeable about the services available to 
her and her family. Ultimately though, it must be the decision of the patient as to whether 
her family or the patient should attend counselling and at a time when she considers it 
appropriate. 
 
From the data, very little if any emphasis is placed on the well-being of a patient’s family. A 
diagnosis of breast cancer not only has a negative impact on the patient, but impacts on 
her entire family. Allowing a patient’s family to be involved, with the consent of the patient, 
from the moment of diagnosis, would, in most cases, create a supportive environment for 
the patient. This would lead to the patient being able to share her fears and frustrations 
with her family instead of having to deal with the situation on her own. Moreover, this could 
have a positive impact on the patient’s well-being as a supportive and caring environment 
will allow her to cope better with her diagnosis, as well as speed up the recovery process. 
 
5.2.2.5 Link between advice on risk of recurrence and patients’ opinion on 
causes of their breast cancer  
Graham et al. (2002) state that the relation between stressful life experiences and the 
onset of breast cancer has been the subject of considerable research, much of which has 
been characterised by weak design. However, a meta-analysis conducted by Petticrew et 
al. (1999) concluded that the few well-designed studies that have been carried out have 
failed to find a link between stressful life experiences and the onset of breast cancer 
(Graham et al., 2002). 
 
Research has shown that increased levels of physical activity decrease the risk of 
developing breast cancer in the general population by between 20 and 40% (Monninkhof 
et al., 2007; Lahmann et al., 2007; Sprague et al., 2008). There is a greater association in 
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postmenopausal women, although Maruti et al. (2008), Suzuki et al. (2008) and Howard et 
al. (2009) maintain that increased physical activity may decrease the risk for 
premenopausal breast cancer as well. Due to physical activity being one of the few 
modifiable risk factors, it may provide a target to add to breast cancer prevention in 
BRCA1/2 mutation carriers (Pijpe et al., 2009). However, the results of this study have 
shown only one breast cancer survivor stating insufficient exercise as a probable cause of 
her developing breast cancer. 
 
5.2.2.6 Provision of counselling for the patient at the time of diagnosis  
The patients experienced various emotions ranging from “numbness” and “denial” to 
“devastation” and “shock.” Since the sample group was so small, it was not possible for 
the researcher to classify the range of emotions under a specific type of emotion. 
However, it can be said that all the patients went through a number of different and varying 
degrees of emotions. According to Avis et al (2005), preparing younger women for the 
impact of breast cancer may also prove beneficial. However, in our setting with cancer 
affecting all age groups, it is imperative that counselling be provided across all ages. 
 
Tessaro et al. (1997) and Mouchawar et al. (1999) found that women with and without a 
diagnosis of breast cancer were reported to have poor or limited knowledge of the 
availability of genetic testing for breast cancer risk, the information provided by testing, and 
the implications of testing.  Bottorff et al. (2002) indicate that in clinical settings, knowledge 
of genetic testing for breast cancer risk and its limitations may reduce the interest in testing 
in high-risk individuals, although a similar association has not been observed amongst 
women in the general public. 
 
Henselmans et al. (2009) point out that when women are diagnosed with breast cancer, 
they are confronted with different stressors, such as surgery, the spread of the cancer, 
side effects and recurrence, throughout the course of the illness. It is important that in the 
face of these stressors, women are able to exercise personal control, which is the belief 
that life is not ruled by fate but that a person is able to influence the important events or 
situations in their life (Henselmans et al., 2009). This belief is related to a variety of 
positive outcomes such as a lower risk of disease (Bosma et al., 2005), successfully 
adjusting to the illness (Helgeson et al., 2004) and survival (Surtees et al., 2006). 
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The patients’ responses in this study show that women have very different needs at the 
time of diagnosis. Whilst some patients felt more comfortable confiding in a normal general 
practitioner (GP), others wanted more information and would therefore feel more 
comfortable talking to a specialist. Furthermore, some patients did not want to be 
overburdened by medical knowledge and would therefore opt to talk to a layperson. 
 
In addition, from the data gathered from the breast cancer survivors, the researcher 
noticed that information on genetics, recurrence, prognosis and family risk appeared to be 
more important to the women with teenage daughters. This emphasised that women would 
want to know whether their daughters were also at risk of developing breast cancer.  
 
Nationally, there are approximately six genetic services in South Africa. However, these 
services are not specific to cancer genetics. At the time of the study no genetic services 
were available specifically for breast cancer and the only genetic service available for 
KwaZulu-Natal was based in Durban. In terms of referral, once a patient was diagnosed 
with breast cancer, either at Northdale or Edendale Hospitals, the patients were then 
referred for treatment to Grey’s Hospital, which is a tertiary hospital in Pietermaritzburg. 
However, even at Grey’s hospital no genetic counselling services were available for the 
patient or her family. 
 
5.2.2.7 Provision of counselling for the patient after surgery  
The findings of this study indicate that counselling of women who have undergone a 
mastectomy is imperative in helping them deal with and accept their change in body 
configuration. All four patients indicated that counselling either helped or would have 
helped them to cope better. 
 
Hopwood (2000) noted that women who are at risk of developing breast cancer are likely 
to differ in the type and amount of information they need, as well as in their preferences for 
involvement in decision-making processes. 
 
Many doctors and surgeons, however, do not properly think through the needs of breast 
cancer patients. De Bock et al. (2001) found that in 30% of individual consultations, 
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general practitioners did not follow the advice of the clinical geneticist. The researcher is of 
the opinion that health professionals need to realise that a diagnosis of breast cancer 
affects not only the patient, but the family as well. This aspect should be seriously 
considered, as family will be many of these women’s support system through this 
traumatic period. Women who do not undergo a mastectomy and instead undergo 
chemotherapy or radiation therapy, depend greatly on the support of their family. If 
appropriate information and counselling is not offered, it leads to patients’ harbouring bitter 
emotions, as is evident from patients’ responses.  
 
The four patients interviewed indicated that prior to being diagnosed with breast cancer, 
their knowledge about breast cancer was minimal in that they knew it was a cancer that 
affected females, but were not familiar with the risk factors associated with breast cancer, 
the advantages and disadvantages of the various therapies, nor did they know about 
genetic counselling or risk assessment. However, since being diagnosed, they had been 
self-educated about risk factors and the various therapies for breast cancer, yet only one 
respondent (25%) indicated that she had later learnt about genetic counselling, which she 
had sent both her daughters for. All four patients attributed their increase in knowledge to 
reading books and magazines, talking to other female breast cancer survivors, and 
through attending support groups. This further proves the need for education and 
counselling for women diagnosed with breast cancer. The healing process takes a long 
time and counselling provides the necessary support through this trying time. 
 
5.2.3 Genetic counselling, risk assessment, awareness and education for 
family members of breast cancer patients 
5.2.3.1 Genetic counselling and risk assessment for family members of 
breast cancer patients  
Hopwood (2000) points out  that identification of breast cancer predisposing genes has 
created a demand for personalized risk information in families with a family history of 
cancer, prompting the development of services to respond to this need, and genetic risk 
counselling for women with histories of familial breast cancer is widely supported 




The findings of this study indicate that 40% (n=2) of the female respondents were offered 
this type of counselling and were not interested. Of the remaining 60% (n=3), 20% (n=1) 
indicated that although not counselled, genetic counselling would have been of benefit, 
while 40% (n=2) indicated that they were counselled, with one participant indicating that it 
helped her understand how breast cancer could affect her.  
 
Brandt et al. (2002) and van Asperen et al. (2002) stress  that the reason many women at 
increased breast cancer risk apply for genetic counselling and DNA testing is to reduce 
uncertainty, and the need for information on surveillance and surgery. This means that 
many counselees expect to receive a clear positive or negative result (Press et al., 2001; 
Frost et al., 2004). However, Vos et al. (2008) emphasised that approximately 90% of the 
results do not provide certainty and the communicated cancer risks and risk management 
options remain solely based on family history. 
 
According to Evans et al. (1993) and Cull et al. (1999), very few women had an accurate 
view of their chances of developing breast cancer before they underwent genetic risk 
counselling, whilst the majority of women tended to either over- or underestimate their 
risks.  Furthermore, women in the USA and Canada appeared to overestimate their risk 
(Lerman et al., 1994; Lerman et al., 1995; Smith et al., 1996) to a greater extent than 
women in the UK, who were more likely to underestimate their risk (Evans et al., 1993; 
Cull et al., 1999). Even though genetic risk counselling has been shown to significantly 
improve the accuracy of risk perception (Evans et al., 1993; Cull et al., 1999; Watson et 
al., 1999), it has been found that up to 30% of UK women and 66% of US women continue 
to report exaggerated risks of cancer. 
 
According to Pijpe et al. (2009), BRCA1 and BRCA2 mutation carriers have a high lifetime 
risk of developing breast cancer. Clarke et al. (2008) found that some participants in their 
study struggled with their children’s decision on genetic testing, whilst others, although 
recognising the need that their child would ultimately have to be tested, were concerned 
for the consequences or costs that might ensue if the result was positive. According to 
Smith et al. (2008), information provided by genetic testing is highly beneficial, but may 




5.2.3.2 Precautionary measures, creating awareness and educating family 
members on breast cancer  
Tryggvadottir et al. (2006) suggest that it is possible that the incidence of breast cancer 
diagnosis according to a woman’s age is highly influenced by the amount of awareness 
she has been subjected to, as well as screening. This would be in keeping with the fact 
that when a woman is diagnosed with breast cancer, her family becomes more aware of 
the disease therefore taking further precautionary measures to ensure either prevention or 
early detection of the disease.  
 
Silberman (2014) states that, in terms of raising awareness, enough is being done. 
Children from elementary through to high school are aware about breast cancer and are 
able to explain that particular bracelets they wear are to show their support of breast 
cancer (Silberman, 2014). In terms of educating family members, Warner et al. (2003) 
points out that education about risk of developing breast cancer is extremely important for 
women with a family history of breast cancer, as this may assist in reducing their anxiety 
as well as the avoidance of unnecessarily being transferred to high-risk clinics for further 
investigations which are not required. 
 
This study found that 60% (n=3) of the female respondents are taking precautionary 
measures by either following a healthy eating plan or going for regular check-ups. The 
majority of the respondents (88%; n=7) were of the opinion that enough is being done to 
create awareness on breast cancer.  
 
5.3  Limitations of the study  
Although due diligence was maintained in order to ensure the integrity of the study the 
following limitations of the study were identified: 
 
5.3.1 Sample size 
The sample of this study is very limited with only fifty-six participants and therefore not 





5.3.2 Selection bias  
The study was conducted in an urban area, which resulted in mainly White and Indian 
respondents. The non-recruitment of Coloured and limited participation of Black females in 
the study is considered a limitation. All respondents were literate with at minimum, a Grade 
10 pass. The respondents were therefore literate and able to understand and respond to 
questions. Respondents from the general public were purposely selected to ensure that 
responses to questionnaires will be easily obtained and participants could be easily 
followed-up. In addition, the involvement of respondents from the CANSA support group 
only, for breast cancer survivor respondents was also limiting in terms of racial 
representivity. 
 
5.3.3 Information bias 
The richness of the information collected and analysed was limited by the design of the 
questionnaire; non-explanation to participants about the concepts of genetic counselling 
and risk assessment. This may have been one of the reasons many women from the 
general public indicated their disinterest or uncertainty in attending a risk assessment 
session. 
 
5.3.4 Age of data 
Data for this study was collected more than 10 years ago. During this time, advances in 
medical and social contexts made, would result in the findings of a similar study today, 
differing to the findings of the current study. 
 
5.4  Summary  
This chapter discussed the key findings of the study in relationship to international studies. 
A comparison with the literature reviewed indicated that while significant effort has been 
placed on creating awareness on breast cancer, there is a deficiency in terms of educating 
family members about risks of breast cancer as well as genetic counselling and risk 
assessment for women at high risk. This lack of knowledge has a negative impact on the 
use of these services and ultimately impacts on early detection. Without early detection 
and appropriate management of breast cancer, mortality due to breast cancer will continue 
to rise.  
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CHAPTER VI: CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 Introduction  
This chapter summarises the study and makes recommendations to strengthen the uptake 
for genetic counselling and assessment for breast cancer in women of all races in South 
Africa and for further research. 
 
6.2 Conclusion 
Strengthening the health care system through increasing the knowledge of health 
professionals on genetic counselling and risk assessment will contribute to the uptake of 
these services. Presently, neither breast cancer patients and their families, nor women 
from the general public are aware of the availability of such services.  
 
This study has found that only 25% of family members went for genetic counselling, which 
has resulted in them taking the necessary precautionary measures and understanding 
their risks involved in the development of breast cancer. A further 25% of respondents 
indicated that although they were never offered this type of counselling, they would have 
considered this beneficial in further understanding their risks in developing breast cancer, 
as well as obtaining a better understanding of what breast cancer is.  
 
In addition, the lack of educating patients and their families on the availability of genetic 
counselling has negatively impacted many patients and families, as they were not provided 
with the opportunity to attend genetic counselling sessions. This has impacted on the 
uptake of genetic counselling services within the families of breast cancer patients.  
 
6.3 Recommendations  
Based on the findings of the study, the researcher makes the following recommendations 







6.3.1 Modifying factors 
a. Knowledge 
Education and awareness raising programmes on the importance of breast cancer 
screening and risk assessments for women at high risk should be made available. 
This will provide women with the appropriate knowledge and information to make 
the necessary decisions for prevention, early detection, treatment and survival.  
 
b. Race and socioeconomic factors 
Due to the cultural diversity of the South African population, education and 
awareness raising programmes should be culturally appropriate. Furthermore, the 
level of literacy varies drastically and this should be taken into consideration when 
these programmes are developed so as to ensure all women in South Africa are 
provided with the same information, relevant to their level of education and 
understanding.  
 
6.3.2 Cues to action 
a. Policy 
An integrated strategy for the early detection and treatment of breast cancer should 
be developed. The strategy must focus on education about breast cancer, 
strengthening methods for early detection and treatment, genetic counselling and 
testing, as well as psychosocial support for both patients and families. 
 
Strengthening the provision of genetic counselling and risk assessment services to 
high-risk breast cancer survivors and their female family members is essential. This 
will enable women to understand their risks and to be identified in the early stages 
of breast cancer. Early identification and treatment will decrease the mortality rate 
due to breast cancer in South Africa.  
 
It is important that not only survivors but health professionals also understand its 
importance. Hence, enhanced information should be provided to health 




Family members should also be counselled to help them cope emotionally and 
mentally with the diagnosis of the patient and to also understand how they can 
provide the patient with the necessary support throughout the treatment process.  
Health care providers must take the opportunity at facilities to conduct health talks 
that are both culturally and linguistically appropriate, to patients and explain what 
breast self-examination is and when and how it should be conducted. In addition, 
health care providers must explain the services available for detection of breast 
cancer and what this service entails. If genetic counselling services are offered by 
a clinic, women at risk should be afforded the opportunity to attend the genetic unit 
to further understand what it is about. 
 
A multi-sectoral team should be available to offer every patient the opportunity to 
undergo counselling, whether for herself or her family. It should be the 
responsibility of the doctor who diagnoses her breast cancer to provide her with 
this information. However, this information about counselling should be suggested 
and not imposed upon the patient. Equipping the patient with relevant information 
at the time of diagnosis enables her to be knowledgeable about the services 
available to her and her family. Ultimately though, it must be the decision of the 
patient as to whether she or her family should attend counselling and at a time that 
she considers appropriate. 
 
Patients should speak to a genetic counsellor, psychologist, medical doctor, 
medical nurse, social worker, or any other person they would feel most comfortable 
with.  
 
There is an urgent need for improved training of health professionals on breast 







6.3.3 Likelihood of action 
a. Perceived benefits without perceived barrier 
Female family members of breast cancer patients should be educated about their 
increased risk and advised about screening and risk assessment services they 
should utilize. Information must be provided as clearly as possible to assist with 
decisions on screening and risk assessment. 
 
A diagnosis of breast cancer has a negative impact not only on the patient, but on 
her entire family. Allowing a patient’s family to be involved, with the consent of the 
patient, from the moment of diagnosis, would, in most cases, create a supportive 
environment for the patient. This would lead to the patient being able to share her 
fears and frustrations with her family instead of having to deal with the situation on 
her own. Moreover, this could have a positive impact on the patient’s well-being, as 
a supportive and caring environment will allow her to cope better with her 
diagnosis, as well as speed up the recovery process. 
 
Every patient should be offered the opportunity to undergo counselling, whether for 
herself or her family. It should be the responsibility of the doctor who diagnoses her 
breast cancer to provide her with this information. However, this information about 
counselling should be suggested and not imposed. By equipping the patient with 
relevant information at the time of diagnosis, enables the patient to be 
knowledgeable about the services available to her and her family. Ultimately 
though, it must be the patient’s decision on whether she or her family should attend 
counselling and at a time that she considers appropriate. 
 
6.3.4 Other recommendations 
Education programmes targeting men should be developed to encourage men to screen 
for breast cancer and make them aware of the fact that breast cancer does not only affect 
women. These education programmes should include the positive medical experiences 





Further research should be conducted on the following topics: 
• An investigation in the South African context on ways in which to overcome the 
barriers to genetic counselling and risk assessment to increase the use of genetic 
services 
• An exploration of men’s perceptions of breast cancer and its detection 
• Investigation of culturally appropriate strategies to overcome barriers to the early 
detection and treatment of breast cancer  
• Health care professionals’ perceptions of the role and involvement of family 
members in breast cancer patient support and rehabilitation 
 
6.4 Summary  
Genetic counselling and testing is not well-known amongst the general population, breast 
cancer survivors or their family members. In order to ensure genetic counselling and risk 
assessment services are strengthened and utilized, education and awareness is required. 
Education by health care professionals, provision of information, education and 
communication material on breast cancer and breast cancer services will further contribute 
to an increase in the number of people utilizing the service, early detection of the disease, 
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Annexure 1: Self-administered questionnaire for breast cancer patients 
 
SELF-ADMINISTERED QUESTIONNAIRE FOR BREAST CANCER PATIENTS 
 
1. What is your age? 
  
2. Please indicate your race: 
  Black 
  White 
  Indian 
  Coloured 
  
3. Is your ethnicity mostly Jewish? 
  Yes 
  No 
  
4. What is your height and weight? 
  
5. Is your ethnicity mostly Jewish? 
  Yes 






6. Do you usually drink one or more servings of alcohol per day? 
  Yes 
  No 
 
7.         Do you eat three or more servings of vegetables per day? 
 (One serving is about one cup of raw leafy greens or half a cup of other 
vegetables, raw or cooked). 
  Yes 
  No 
  
8. Were you exposed to significant radiation in the past? 
  Yes 
  No 
  
9. How old were you when you first menstruated? 
  Younger than 15 
  Older than 15 
  
10. Are you currently taking birth control pills? 
  Yes 







11. How many children have you given birth to? 
  None 
  One 
  Two or more 
  
12.        What was your age at first live birth? 
  Unknown 
  No births 
  <20 
  20 to 24 
  25 to 30 
  >30 
  
13. Are you menopausal? 
  Yes 
  No 
  
14. Have you ever had a hysterectomy (removal of the uterus)? 
 (Having a hysterectomy does not increase your risk of getting breast cancer). 
  Yes 






15. Do you examine your breasts monthly? 
  Yes 
  No 
  
16. Have you ever had any type of cancer, except for non-melanoma skin cancer? 
  Yes 
  No 
  
17. Have you ever conducted any of the below-listed examinations? 
  Breast self-examination 
  Clinical breast examination 
  Both 
 
18.        About yourself.  What about you? 
  Never had breast disease 
  Have had previous lumps or cysts 
  Have had previous breast cancer 
  
19. Has your sister ever had breast cancer? 
  Yes 






20. Has you mother ever had breast cancer? 
  Yes 
  No 
  
21. Have you ever had a breast biopsy? 
  Yes 
  No 
  
22. How many breast biopsies, positive or negative, have you had? 
  1 
  >1 
  
23.        Have you had at least one breast biopsy with atypical hyperplasia (a 
precancerous condition)? 
  Yes 
  No 
  Unknown 
 
24.       Before being diagnosed with breast cancer, were you ever advised about the 
potential risk factors for breast cancer? 
  Yes 
  No 
  




25. Before being diagnosed, did you have any of these signs or symptoms?  Please 
tick the appropriate block. 
  A lump or thickening in the breast or armpit 
  Changes in the skin – dimpling, puckering or redness 
  Changes in the nipple – direction of the nipple or an unusual discharge 
  Changes around the nipple – unusual rash or sore area 
  Changes in the size or shape of the breast 
  
26. Do you take oestrogen-containing oral contraceptives? 
  Yes 
  No 
  
27. Were you given the option to have a breast cancer risk-assessment counselling 
session? 
 (In this type of counseling session patients learn more about their cancer risks, 
screening options, and gene testing for hereditary cancer). 
  Yes 
  No 
  
 
 If yes, please answer the following: 
 (i) Who, or what agency, did the assessment? 
   
 (ii) What formula was used to calculate the risk? 
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28. If you answered no to the above question, would you be interested in attending 
a breast cancer risk-assessment session, if not for yourself, then for family and 
friends? 
  Yes 




1. What method of detection was used to diagnose you as a breast cancer 
patient? 
  Mammography 
  Biopsy 
  Clinical breast examination 
  Breast self examination 
  
2. At which stage of breast cancer were you when you were first diagnosed? 
  Stage 0 
  Stage 1 
  Stage 2 
  Stage 3 
  Stage 4 
  Recurrent 
  Unknown 
  




4. After being diagnosed with breast cancer, what type of therapy were you 
given?  Tick the appropriate box(es) 
  Chemotherapy 
  Radiation Therapy 
  Surgery 
 
5.        Were you advised about the advantages and disadvantages of the different 
types of therapy? 
  Yes 
  No 
  
6. If you were given either chemotherapy and/or radiation therapy, please state 
what the side effects of either treatment was. 
 Chemotherapy:  
  




7. If you opted for surgery, what type of surgery did you undergo? 
 
  Total Mastectomy: 
  an operation to remove the breast or as much of the breast as 
possible;  some lymph nodes under the arm are also removed. 
  Breast Conserving Therapy or Lumpectomy: 
  an operation to remove the cancer and not the breast 
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  Modified Radical Mastectomy: 
  removal of the whole breast, most of the lymph nodes under the 
arm and often the lining over the chest muscles. 
  Radical Mastectomy: 
  removal of the breast, both chest muscles, all of the lymph 
nodes under the arm, and some additional fat and skin. 
  
8. Only answer if you have undergone breast surgery 




9. After being diagnosed with breast cancer, is there any specific diet you have 
been encouraged to follow? 
  Yes 
  No 
  
10. How many times a week do you eat red meat? 
  None 
  1 to 3 






11. After being diagnosed with breast cancer, is there a specific 
physical/exercise programme you were encouraged to follow? 
  Yes 
  No 
  
12. How often do you exercise aerobically (e.g. brisk walking or jogging)? 
  Never 
  Less than once per week 
  Once or twice per week 
  At least three to four times per week 
  
13. How long do you exercise for each time? 
  None to 15 minutes 
  16 to 30 minutes 
  More than 30 minutes 
  
14. Are you taking Tamoxifen? 
(Tamoxifen is a medicine that can reduce the risk of developing breast 
cancer in high risk women.  Its benefit to normal risk women is unknown). 
  
15. Within the past year have you been examined by a physician and have had a 
negative mammogram? 
  Yes 




16. After being diagnosed with breast cancer, have you ever been advised about 
factors which reduce the risk of developing breast cancer?  (Factors such as 
limiting the use of hormone replacement therapy, avoiding obesity, staying 
physically active). 
  Yes 
  No 
  
17. Were you given the opportunity to speak to someone who would explain 
breast cancer?  Tick the appropriate box. 
  Genetic counselor 
  Psychologist 
  Medical Doctor 
  Medical Nurse 
  Social worker 
  Dietician 




18. What, in your opinion, were some of the risk factors that affected you? 










19.       What do you think was the cause of your cancer? 




Early menstruation (<15 years of 
age) 
 
Early live birth (<24 years of age)  
Late live birth (>25 years of age)  
Oestrogen contraceptives  
Family history  
  
  
20. Do you know of any causes of cancer in general? 
  
  
21. Is having the option of reconstructive surgery important to you? 
 _________________________________________________________________ 
22. Have you had reconstructive surgery? 
  Yes 






23. If you have undergone reconstructive surgery, was it successful? 
  Yes 
  No 
  







25. Was your family given the opportunity to undergo counselling? 
  Yes 
  No 
 












Annexure 2: Self-administered questionnaire for women from the general public 
 
SELF-ADMINISTERED QUESTIONNAIRE FOR WOMEN FROM THE GENERAL 
PUBLIC 
 
1. What is your age? 
  
2. Please indicate your race: 
  Black 
  White 
  Indian 
  Coloured 
  
3. Is your ethnicity mostly Jewish? 
  Yes 
  No 
  
4. What is your height and weight? 
  
5. Do you smoke? 
  Yes 







6. Do you usually drink one or more servings of alcohol per day? 
  Yes 
  No 
 
7.         Do you eat three or more servings of vegetables per day? 
 (One serving is about one cup of raw leafy greens or half a cup of other 
vegetables, raw or cooked). 
  Yes 
  No 
  
8. Were you exposed to significant radiation in the past? 
  Yes 
  No 
  
9. How old were you when you first menstruated? 
  Younger than 15 
  Older than 15 
  
10. Are you currently taking birth control pills? 
  Yes 







11. How many children have you given birth to? 
  None 
  One 
  Two or more 
  
12. What was your age at first live birth? 
  Unknown 
  No births 
  <20 
  20 to 24 
  25 to 30 
  >30 
  
13. Do you examine your breasts monthly? 
  Yes 
  No 
  
14. Have you ever had any type of cancer, except for non-melanoma skin 
cancer? 
  Yes 
















16.      Have you ever conducted any of the below-listed examinations? 




Early menstruation (<15 years of 
age) 
 
Early live birth (<24 years of age)  
Late live birth (>25 years of age)  
Oestrogen contraceptives  
Family history  
  Breast self-examination 
  Clinical breast examination 
  Both 
  
17. About yourself.  What about you? 
  Never had breast disease 
  Have had previous lumps or cysts 
  Have had previous breast cancer 
  
18. Has your sister ever had breast cancer? 
  Yes 
  No 
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19. Has you mother ever had breast cancer? 
  Yes 
  No 
  
20. Have you ever had a breast biopsy? 
  Yes 
  No 
  
21. How many breast biopsies, positive or negative, have you had? 
  1 
  >1 
  
22.      Have you had at least one breast biopsy with atypical hyperplasia (a 
precancerous condition)? 
  Yes 
  No 
  Unknown 
  
 
Only answer questions 23 and 24 if you have been diagnosed with breast 
cancer 
 
23. Before being diagnosed with breast cancer, were you ever advised about 
the potential risk factors for breast cancer? 
  Yes 




 If yes, by whom were you advised? 
  
  
24. Before being diagnosed, did you have any of these signs or symptoms?  
Please tick the appropriate block. 
  A lump or thickening in the breast or armpit 
  Changes in the skin – dimpling, puckering or redness 
  Changes in the nipple – direction of the nipple or an unusual discharge 
  Changes around the nipple – unusual rash or sore area 
  Changes in the size or shape of the breast 
  
25. Do you take oestrogen-containing oral contraceptives? 
  Yes 
  No 
  
26. If given the opportunity, would you be interested in consulting with a 
genetic counsellor to assess your risk of developing breast cancer? Any 
other reasons  
   
   
  






Annexure 3: Semi-structured interview with breast cancer patients 
 
SEMI-STRUCTURED INTERVIEW WITH BREAST CANCER PATIENTS 
 
Interview for breast cancer patients 
The following questions were asked to breast cancer patients under the headings of: 
 pre-interview orientation, 
 period until diagnosis, 
 period surrounding the mastectomy, 
 after mastectomy, and 
 family/friends attitudes 
 
A.  Pre-interview orientation 
1. At the beginning of the interview the patient should state her name, age, race, and  























4. What is their relationship to you?  
 
Family member’s name Relationship to you Type of cancer 
   
   
   
   
 
B.  Period until diagnosis 
1.  What were your earliest signs/symptoms that prompted you to see a doctor?  
      
       
        
 
        
 












   




















            
 
            
 
          
            
 
            










Description of disease 
Chance of reoccurrence 
Prognosis 





Yes No Consult with a genetic counsellor 
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7.  Were you happy with the information? 
 
     
8. Did you understand the information that was given to you? 
 
 




10.1 If counsellor was suggested: 
      10.1.1 Did you visit a counsellor? 
 
 
      10.1.2 What type of counsellor did you visit? 
 
        






      10.1.4 Would you have liked to be counselled about the genetics and risks               












10.2 If no counselling was suggested: 
      10.2.1 Would you have liked to visit a counsellor? 
 
 
      10.2.2 What type of counsellor would you have liked to visit? 
 
 
      10.2.3 Would you have liked to be counselled about the genetics and risks  
                 involved with breast cancer? 
 
 
11. Would you have liked to know more about the disease, breast cancer, such as the 







         
       
 

















C.  Period surrounding the mastectomy 
 
1. How long after diagnosis did you have a mastectomy? (Time response) 
 
 




3.1 If yes 
      3.1.1 What type of counsellor did you visit? 
 
     





      3.1.3 Would you have liked to know more? 
 
 





   3.2 If no counselling was received before your mastectomy: 










      3.2.2 What type of counsellor would you have liked to visit? 
 
 






D.  After mastectomy 
1. How long has it been since you’ve had a mastectomy? 
_________________________________________________________ 
 


























6.1 If yes: 
6.1.1 What type of counsellor did you visit? 
 
 







      6.1.3 Would you have liked further counselling? 
 
 
6.2 If no counselling was received: 
      6.2.1 Would you have liked to visit a counsellor? 
 
 
      6.2.2 Do you think a counsellor would have helped you cope better with your  
               mastectomy? 
 
 
7.  Did you accept the change in your body’s configuration immediately? 
 
 












9. If yes, how long did it take you to accept it? (Time response) 
 
 










12. Do you now feel the information you were given at your first diagnosis was  
      sufficient? 
 
 
13. If not, what other information do you feel should have been given to you to help  




















15. If yes, what has helped you become wiser? 
 
        
       
 




E.  Family/friends attitudes 
1. Did you inform family members and friends of your diagnosis? 
 
 
2.  If yes, when did you inform them? (Time response) 
 
 
































6. Were any of your family members given the opportunity to be counselled? 
 
 
7. If yes: 
      7.1 What type of counsellor did you visit? 
 
 
      7.2 Was the counselling of any help? 
 
 
7.3 Was your family counselled on the genetics of the disease and the risks to  
       them as family members? 
 
    
7.4 If not, do you think such information is important and relevant? 
 
    
8. If no counselling was obtained: 
      8.1 Would you have liked to visit a counsellor? 
 
 
      8.2 Do you think it is important for family members to be counselled? 










8.3 What type of counsellor would you have liked to visit? 
              
 
8.4 Do you think a counsellor would have helped your family cope better with  
      your breast cancer? 
        
       
8.5 What type of information would you have liked the counsellor to give your  






9. Was any risk calculations made for family members? 
 
    
10. Would you be interested in knowing the risks of your family members to breast cancer? 
 
 
   11. Do you think enough is being done about: 
      11.1 Creating an awareness of breast cancer? 
 
 












Annexure 4: Semi-structured interview with family members of breast cancer 
patients 
 
SEMI-STRUCTURED INTERVIEW WITH FAMILY MEMBERS OF BREAST CANCER 
PATIENTS 
 
At the beginning of the interview family members should state their names, age, sex, and 
relationship to patient. 





   
 










2. Did the patient mention any suspicions before diagnosis? 
 
 









4. When were you informed about her diagnosis? (Immediately/weeks/months/etc) 
________________________________________________________________________ 
 
5.  At the time of diagnosis, did you have any understanding of what cancer was? 
 
 
6. After the diagnosis, did you gather more information about breast cancer? 
 
 







8.  Do you feel that you now have a better understanding and knowledge about breast  
     cancer, or, would you like to learn more?  (If they would like to learn more) What more 





9.  Were you offered any counselling to help you cope with your family member’s   
     diagnosis and mastectomy? 
 
 
10.1 If yes: 










      10.1.2 Was the counselling of any help? 
 
      
 






      10.1.4 Were you counselled about the genetics and risks involved with breast  
                  cancer? 
 
 
      10.1.5 If not, would you have liked to be counselled on the genetics and risks  
            involved with breast cancer? 
 
 
10.2  If no counselling was obtained: 
      10.2.1 Would you have liked to be counselled as a family? 
 
 


















      10.2.4 Would you have liked to be counselled on the genetics and risks of breast  
                 cancer? 
 
 
11. Would you like to undergo a breast cancer risk assessment should you be given  
      the opportunity? 
 
 
12. Do you fear getting the disease? 
________________________________________________________________________ 
 






14. As a female offspring of a woman with breast cancer, what precautionary  









15. Do you think enough is being done about: 
      15.1 Creating an awareness of breast cancer? 
 
       
       15.2 Educating family members of breast cancer patients as to what exactly breast  
              cancer is? 
 
 
 
 
 
 
Yes No 
Yes No 
